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Abstract 
The natural environment is burdened with a broad range of toxic chemicals, and 
there is a need to develop a tool that can accelerate the pace at which we learn how 
chemicals impact disease.  This work developed an artificial neural network (ANN) 
based model that constructed chemical-disease relationships for chemicals found in the 
Comparative Toxicogenomics Database.  A new chemical classification system, based on 
the molecular weight, hydrogen donors, and hydrogen acceptors, was created to identify 
chemicals with a unique number that is directly related to these structural properties of 
the chemical.  Diseases were grouped into 27 categories and the chemical-disease 
associations were made between the chemical and its associated disease category.  The 
ANN model was successfully trained and tested to associated 75 chemical with the 27 
disease categories. Simulations with training-validation-testing ratios of 70-15-15 percent 
produced coefficients of determination equal to 0.99, and the Levenberg-Marquardt 
backpropagation function provided the best network performance.  To help validate the 
model, the ANN was also used to evaluate chemical-disease relationships for three 
uncurated chemicals.  Results showed that ANNs have the potential to predict disease 
associations for uncurated chemicals and to guide research for curated chemicals that 
may require further toxicological testing. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
To my wife and grandpa  
 
 
 
 
 v 
 
Acknowledgments 
I would like to thank my advisor Dr. Willie Harper for his guidance and direction 
throughout the process of this thesis effort.  His input was extremely valuable and greatly 
appreciated.  I would also like to thank committee members Lt Col Tay Johannes and Lt 
Col Dirk Yamamoto for their support and insight.  Additionally, I would like to thank Dr. 
Michael Grimalia for his efforts in obtaining data files from the CTD. 
 vi 
 
Table of Contents 
Page 
Abstract .............................................................................................................................. iii 
Acknowledgments................................................................................................................v 
Table of Contents ............................................................................................................... vi 
List of Figures .................................................................................................................. viii 
List of Tables ..................................................................................................................... ix 
I.  Introduction .....................................................................................................................1 
Significance of Research .................................................................................................4 
Implications of Research .................................................................................................5 
II. Literature Review ............................................................................................................6 
The relationships between chemical properties and disease ...........................................6 
Using Artificial Neural Networks in medical research ...................................................7 
ANN in diagnosis ........................................................................................................9 
ANN in predictions ...................................................................................................11 
III. Research Objectives .....................................................................................................13 
IV. Methodology ................................................................................................................15 
Overview .......................................................................................................................15 
Chemical Classification System ....................................................................................15 
Data ...............................................................................................................................17 
Chemicals .................................................................................................................18 
Diseases ....................................................................................................................31 
Artificial Neural Network .............................................................................................33 
Input and Output Data ...................................................................................................34 
Simulations ....................................................................................................................36 
Analysis and Results .....................................................................................................38 
V. Analysis and Results .....................................................................................................40 
ANN Training Results ..................................................................................................40 
ANN Model Performance for Curated Chemicals ........................................................56 
Effect of Training Ratio on Model-Predicted Disease .............................................56 
Chemical Trends for Undertrained Model Simulations ...........................................58 
 vii 
 
Chemical Trends for Overtrained Model Simulations .............................................61 
ANN Model Performance for Uncurated Chemicals ....................................................63 
VI. Conclusions and Recommendations ............................................................................68 
Research Conclusions ...................................................................................................68 
Recommendations for Future Research ........................................................................70 
Appendix A: MATLAB ANN Code ..................................................................................71 
Appendix B: Input and Output Matrices ............................................................................75 
Appendix C: Additional MATLAB Training Sessions ...................................................106 
Appendix D: TVT Graphs ...............................................................................................122 
Appendix E: List of Training Functions ..........................................................................128 
Appendix F: Training Function Plots ..............................................................................130 
Appendix G: Uncurated chemical data ............................................................................146 
References ........................................................................................................................148 
Vita  ..................................................................................................................................154 
  
 viii 
 
List of Figures 
Page 
Figure 1: New Chemical Classification Example ............................................................. 17 
Figure 2: Artificial Neural Network Example .................................................................. 34 
Figure 3: Typical MATLAB ANN Training Session ....................................................... 41 
Figure 4: Typical MATLAB Actual Disease versus ANN Derived Disease Outputs Plot
 ................................................................................................................................... 44 
Figure 5: Typical MATLAB ANN Performance Plot ...................................................... 45 
Figure 6: Typical MATLAB ANN Mean Squared Error Plot .......................................... 46 
Figure 7: Typical MATLAB ANN Regression Plot ......................................................... 47 
Figure 8: Typical MATLAB ANN Training States .......................................................... 48 
Figure 9: Typical MATLAB ANN Error Histogram Plot ................................................ 49 
Figure 10: TVT Ratio Effect on the Coefficient of Determination .................................. 52 
Figure 11: Training Function Effect on the Coefficient of Determination ....................... 55 
Figure 12: Effect of TVT Ratio on MATLAB ANN Derived Disease ............................. 57 
Figure 13: Effect of Undertrained TVT Ratio (50-25-25 %) on MATLAB ANN Derived 
Disease ....................................................................................................................... 59 
Figure 14: Effect of Overtrained TVT Ratio (90-5-5 %) on MATLAB ANN Derived 
Disease ....................................................................................................................... 62 
Figure 15: MATLAB ANN Derived Diseases for NCC Cystaphos ................................. 64 
Figure 16: MATLAB ANN Derived Diseases for NCC 6-HO-BDE-47 .......................... 66 
Figure 17: MATLAB ANN Derived Diseases for NCC 4,4'-diiodobiphenyl .................. 67 
 ix 
 
List of Tables 
Page 
Table 1: Chemical Information ......................................................................................... 20 
Table 2: Disease Groupings .............................................................................................. 32 
Table 3: Species Table ...................................................................................................... 35 
Table 4: Acetone Input and Output Matrices .................................................................... 36 
Table 5: The Effect of TVT Ratio on Network Training Statistics .................................. 51 
Table 6: The Effects of Training Functions on Network Training Statistics .................... 54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 
 
 ARTIFICIAL NEURAL NETWORK PREDICTION OF CHEMICAL-DISEASE 
RELATIONSHIPS USING READILY AVAILABLE CHEMICAL PROPERTIES 
 I.  Introduction 
The natural environment is burdened with a broad range of toxic chemicals, 
including petroleum products, metals, pesticides, pharmaceutical compounds, organic 
solvents, and numerous other hazardous substances. Most of these chemicals have the 
potential to cause ecological harm and they also pose significant risks to human health. 
Toxicological testing has helped reveal the connections between specific chemicals and 
health risk factors, but experimental testing on indicator species is expensive and time 
consuming, while testing on humans is illegal and unethical. There is a need to develop a 
tool that can accelerate the pace at which we learn how chemicals impact disease.  Such a 
tool would allow the benefits of a given chemical to be weighed against the risks to the 
environment and public health. 
Risks to the environment and to public health are governed by the interactions 
between chemicals, environmental factors, and the genes that modulate important 
physiological processes, and there are large databases containing information that can be 
used to advance fundamental understanding. For example, the Comparative 
Toxicogenomics Database (CTD) is a publicly available research resource that includes 
curated data describing cross-species chemical–gene/protein interactions and chemical– 
and gene–disease associations. The CTD contains over 800,000 chemical–gene 
interactions, more than 12,400,000 gene-disease associations, and over 1,300,000
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chemical-disease associations (Davis et al., 2013). These data can be used to develop 
insights into complex chemical–gene and protein interaction networks. 
The existing CTD data can be used to develop a model than can predict the effect 
of chemical structure on public health risk.  For such a model, Artificial Neural Networks 
(ANN) can be used.  ANNs are flexible mathematical models that are capable of 
identifying complex nonlinear relationships between input and output data sets.  These 
models are especially useful when it is too difficult to use conventional mathematical 
equations.  ANNs recognize patterns and they work by converting input data into 
numerical values that are propagated through a network of neurons.  The network of 
neurons processes the data given to the network by attempting to find patterns in the data 
so that inputs can be correlated outputs.  ANNs have been used for a wide range of 
environmental and public health applications and they are ideal when there is a large 
amount of data available for ANN development. 
One obstacle in investigating chemical-disease relationships is the lack of a useful 
chemical classification system; one that uses specific chemical characteristics to assign 
chemical identification numbers. Currently, several individual classification systems 
provide unique classification numbers for each chemical; however, these numbers are not 
related to the properties of the chemical and often are randomly assigned. Therefore, 
developing a modified chemical classification system is an important task for the 
development of chemical–disease relationships. It would permit policy makers and 
scientists to anticipate diseases that would be likely associated with new chemicals or 
existing chemicals that require further testing. 
 3 
 
The Environmental Protection Agency (EPA) and National Science Foundation 
(NSF) have expressed interest in chemical-disease relationships for the purpose of 
characterizing chemical lifecycles. In 2013, as part of a joint solicitation, the EPA and 
NSF requested research be conducted that studies the lifecycles of synthetic chemicals, 
including a focus on their impacts on human health and the ecology (National Science 
Foundation, 2013).  ANNs could provide an appropriate tool to investigate chemical life-
cycles, especially when analyzing chemical-disease associations. Understanding how 
chemicals interact in a given environment and how they could affect surroundings play a 
role in the lifecycle of a chemical. 
The EPA could also use an ANN tool to add important chemical association 
information to the Toxic Substances Control Act (TSCA) inventory.  When the TSCA 
was implemented in 1976, over 62,000 chemicals were grandfathered into the inventory 
without any knowledge of their potential affects (Environmental Protection Agency, 
2013).  In the past 38 years, the number of chemicals in the TSCA inventory has grown 
to over 84,000, yet only 4 chemicals are specifically addressed within the TSCA 
document and only a few others have been regulated or banned in the United States 
(Congressional Digest, 2010).  With so many chemicals with unknown chemical-diseases 
associations existing in the TSCA inventory, a simple analytical tool to generate 
chemical-disease association predictions may provide valuable information for 
potentially unknown harmful chemicals.  Using a predictive ANN to generate potential 
chemical impacts could increase the usefulness of the TSCA. 
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Significance of Research 
With the ability to generate predictions of unknown chemical-disease 
relationships, the ANN provides the possibility of being a useful tool for researchers in 
the science and medical fields investigating the potential effects of new chemicals.  A 
network that could point researchers towards the effects a chemical will have could help 
save valuable time and resources when it comes to creating and testing chemicals.  When 
used as a screening and prioritization tool, an ANN may be useful in influencing where 
researchers begin testing and analyzing chemicals.  As the network is expanded through 
future research, it could potentially be used to predict potential interactions other than just 
chemical-disease associations.  Refining the classification number and training the 
network with different outputs could allow the network to predict how chemicals may 
interact if released in to a natural environment.  An ANN with this type of capability 
could be adjusted to work with the Environmental Protection Agency and National 
Science Foundation’s research request for using networks to characterize the lifecycle of 
chemicals.  Additionally, valuable information could be added to the TSCA inventory 
providing data on potentially harmful chemicals which were grandfathered into the 
system with no known associations.  The true significance of using an ANN to predict 
chemical-disease associations will become more evident as further research and testing is 
done to refine the ANN model.  As the model becomes more efficient and produces more 
accurate results, it will be more useful to the scientific community in the screening of 
new chemicals. 
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Implications of Research 
After investigating the research objectives and analyzing the results of the ANN 
simulations, it can reasonably be assumed that a MATLAB ANN can be used to analyze 
chemical and disease data and formulate a network that can possibly predict future 
chemical-disease associations.  The creation and use of a new chemical classification 
system with an ANN was also demonstrated and results show that a new classification 
method could be advantageous when working with chemical-disease interactions.  
Although the classification system developed worked for the simulations conducted in 
this research, it does not mean that the classification represents the best method or uses 
the most appropriate chemical properties in the classification number.  However, it does 
indicate that a classification number based on chemical attributes is certainly a possibility 
and be useful in research and experimentation.  Similar to the classification system, the 
ANN shows the potential for developing networks that can predict chemical-disease 
relationships; however, the current network may not provide the best performance 
possible.  Training-validating-testing (TVT) ratios and training functions play important 
roles in the development of the ANN and show strong correlation to how well the 
network performs, but there are many other factors that can be edited and tested that 
could improve network further.  Using data from the CTD shows that a network could be 
created on a larger scale and not be bound to specific groups of chemicals or diseases.  
Combining the CTD data with the new classification system and ANN confirms that 
chemical-disease association prediction can be accomplished on a large scale, not just in 
smaller quantitative structure-activity relationship research studies. 
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II. Literature Review 
The relationships between chemical properties and disease 
Several studies have explored the relationship between chemical properties and 
health risk factors or physiological impacts on indicator species. For example, Schultz et 
al., 2002 discovered positive relationships among 120 different aromatic compounds and 
estrogenicity based on the number of hydrogen bond donating groups in the aromatic 
compound. They also found that the number of hydrogen bond accepting groups was 
negatively linked to estrogenicity. Fang et al., 2001 looked at 230 natural and synthetic 
steroids and discovered that estrogenicity related negatively to the number of hydrogen 
bond donating groups in the steroid. They also discovered that estrogenicity was 
positively linked to the octanol-water partition coefficients of the steroids. Lipinski et al., 
2012 expanded on this research looking at 2500 organic compounds and discovered 
similar results to that of Fang et al. Quantitative structure activity relationships are not 
limited to only estrogenicity, as they have been used to model numerous other chemical-
disease relationships.  Ren, 2002 found that hydrophobicity and hydrogen bonds could be 
used to predict the toxicity of a chemical and Svetnik et al., 2003 determined molecular 
weight could be used to predict a chemical’s biological activity.  Wu et al., 2013 also 
discovered that hydrophobicity and electron density can predict antibacterial qualities of 
chemicals. This previous work shows that structural properties of chemicals can be used 
to predict associations between chemicals and other factors. 
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Using Artificial Neural Networks in medical research 
ANNs are flexible, mathematical models capable of identifying complex, 
nonlinear relationships in data sets.  They are capable of discovering patterns in large 
amounts of data and have been shown to be useful in environmental and public health 
applications (Beale et al., 2013).  ANNs take a set of input and output data and develop 
correlations between the two data sets by using hidden layers of mathematical formulas, 
weights, and biases.  The formulas are determined by the type of training function 
specified to be used by the network during the simulation.  The weights and biases are 
placed on the input data as the network is tested and they can be adjusted to help improve 
network performance.  After testing the known input and output data with the training 
function formulas, weight, and biases, the network derives outputs that are compared to 
the actual outputs. 
When setting up an ANN, two important parameters of a network are the TV ratio 
and the training function.  TVT ratios establish how the data is divided for use in training, 
validating, and testing the network model.  Training functions are the algorithms that 
determine how the network trains the data while it attempts to find patterns and 
correlations between the input and output data (Beale et al., 2013).  The use of 
appropriate TVT ratios is important for optimizing network performance because the 
ratios will determined if a network is undertrained or overtrained.  Seguritan et al., 2012 
found that testing different training and validation ratios did not provide any significant 
difference in the overall network performance, but adjusting the testing ratio did show 
potential for increasing performance.  Ahmad and Gromiha, 2003 calculated high ANN 
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prediction accuracy rates when using TVT ratios that used a majority percentage of the 
data training the network and Guyon, 1997 found that the ratio of validation data to 
training data should be between 10 and 25 percent.  Singh et al., 2011 compared three 
training functions in a neural network and found the trainbr function provided the best 
network performance, but that more than three functions should be tested to truly find the 
function that best fits the network.  Guenther and Frauke, 2010 showed that resilient 
backpropagation functions performed well in regression ANNs but indicated only three 
types of functions were tested and other functions may provide similar or better results.  
Ferrari and Stengel, 2005 found that algebraic training functions may be used to create 
linear correlations from non-linear datasets with multiple input and output variables. 
Overall, research has shown that ANN can be useful in diagnostic and predictive 
applications when provided the proper data.  ANNs have been used in the medical 
community to address concerns related to specific diseases or groups of diseases. For 
example, Stephan et al., 2009 used ANNs to distinguish between benign and malignant 
prostate cancer and Santos-Garcia et al., 2004 used ANNs to predict morbidity from 
cardio respiratory failure as a result from non-small cell lung cancer pulmonary resection. 
Curtis et al., 2001 used ANNs to associate genotypes with common human diseases and 
Sheppard et al., 1999 used ANNs to predict the risks of contracting cytomegalovirus 
disease after kidney transplantations. Nguyen et al., 2002 used ANNs to predict patient 
susceptibility to meningitis.   
Nearly all of the data used in the ANN analyses for clinical and medical research 
comes from hard to obtain data or data that requires a great deal of effort to acquire.  This 
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hard to obtain data often requires additional testing and information gathering to acquire 
the data needed for the ANN.  This often requires a great deal of time and resources from 
the medical personnel.  For example, Song et al., 2005 used ultrasound image results and 
interpretations from physicians to investigate the ANN diagnosis of breast masses and 
Viazzi et al., 2006 had to obtain cardiac and vascular ultrasound information from 
physicians and adjust it to work in the ANN model.  While useful in medical the medical 
field, many ANN applications require additional data or testing to successfully use the 
network.  
ANN in diagnosis 
ANNs have shown potential to be used in helping doctors diagnose lung diseases 
by analyzing clinical and radiological factors in addition to relying on chest radiographs. 
Abe et al., 2002 and Abe et al., 2004 presented evidence that radiologists could use ANN 
output data, in addition to x-rays, to diagnose lung diseases. Their findings indicated that 
using clinical factors in an ANN could potentially prove to be more useful when 
diagnosing interstitial lung disease. Ashizawa et al., 1999 also found that ANNs used by 
radiologists increased the accuracy of lung diseases diagnosis. Research performed by 
Feng et al., 2012 discovered that ANN proved capable of diagnosing lung cancer as well 
differentiating it from benign lung disease, gastrointestinal cancers, and control patients 
by analyzing various blood levels in patients. 
ANNs are not only limited to be used in diagnosing lung disease. In 2009, 
Babaoqlu et al. concluded that ANN could be used to analyze exercise stress testing data 
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to correctly diagnose coronary artery disease as well predict the locations of lesions near 
the heart. Lux et al., 2013 found that hereditary hemorrhagic telangiectasia could be 
diagnosed by obtaining mid-infrared spectroscopy from blood plasma and analyzing the 
data through an ANN instead of conducting the typical and costly clinical tests.  Matsuki 
et al., 2002 found that by taking clinical parameters and radiologic findings from high-
resolution CT scans and analyzing the data with an ANN, that radiologists could 
accurately diagnose nodules as benign or malignant without having to conduct further 
invasive testing on the patients.  Arterial blood gas values were predicted based off of 
venous blood gas values in an effort to better assess patients with acute exacerbations of 
chronic obstructive pulmonary disease (AECOPD) by Raoufy et al., 2011.  Arterial blood 
gas values provide the best diagnostic evidence of AECOPD but can be difficult to 
obtain.  Using an ANN to correlate venous blood gas values to arterial blood gas values 
provided an accurate method to detect AECOPD hypercarbia.  Deng et al., 1999 found 
that when ANNs were combined with MRIs, physicians were able to successfully 
diagnose Alzheimer’s disease in potential patients and Matake et al., 2006 found that the 
accuracy of radiologist diagnosis of hepatic masses increased when ANN were used to 
analyze nine clinical parameters from computed tomographic scans.  Hamilton et al., 
2006 successfully used ANNs to discriminate between parkinsonian syndrome and 
essential tremors based on the ratio of tracer accumulation between the caudate nucleus 
and putamen. This model provided a tool to diagnose parkinsonian syndrome early 
without confusing it with essential tremors.  
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ANN in predictions 
 In addition to aiding medical professionals in diagnostics, ANNs have also been 
shown to be useful in predicting diseases as well.  The different between predicting and 
diagnosing diseases is diagnosing is identifying a disease or condition that is already 
present.  Predicting uses current data to forecast potential future disease or conditions 
without any current symptoms.  For example, Biglarian et al., 2012 found that ANNs 
were useful is predicting distant metastasis in colorectal patients and that the ANN 
models were more accurate that logical regressions models.  Colak et al., 2008 created an 
ANN model that highlighted promising results for predicting coronary artery disease 
without the need to invasive testing for diagnosis. The work of Cucchetti et al., 2007 
demonstrated that ANNs were more accurate than the current model for end-stage liver 
disease used to prioritize patients with liver cirrhosis for donor organs and Ghoshal et al., 
2008 used ANN to predict the mortality of patients with cirrhosis of the liver. Using 
ANNs for this could help doctors better prioritize transplant candidates, potentially 
reducing the mortality rate of patients waiting for donor organs. Dagli et al., 2012 used an 
ANN to predict anemia in patients with Behcet disease. Their model provided a 99% 
correct anemia prediction rate using prohepcidin and hepcidin levels as well as several 
other common blood parameters. El-Solh et al., 1999 found that ANNs were more 
accurate in predicting pulmonary tuberculosis that medical assessments performed by 
physicians. Recurrence of non-invasive transitional cell carcinoma of the urinary bladder 
was predicted in an ANN model by Fujikawa et al., 2003 and the model proved to be 
more accurate than current prognosis techniques.  Matsui et al., 2002 developed an ANN 
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model that showed promising results for being able to replace old methods of predicting 
prostate cancer in Japanese men.  Although in need of further refinement, the model 
could be used to predict the pathological stage of prostate cancer.   Ning et al., 2006 
predicted levels of hypertension using physician and patients comment data in an ANN.  
ANNs were shown to be a possible tool for predicting Graves’ disease in patients as a 
result of antithyroid drug withdrawal by Orunesu et al., 2004 and Salvi et al., 2002 found 
that ANN could be used to predict the progression of thyroid-associated ophthalmopathy. 
The articles discussed in this literature review represent a sample of the articles 
that can be found on these topics.  It is meant to provide an understanding of previous 
work conducted with chemical-disease relationships and ANNs in the scientific and 
medical research communities by showcasing relevant research.  From analyzing 
previous research related to chemical-disease relationships and the use of ANNs in 
investigating chemical-disease associations, it can be concluded that with proper set-up, 
ANNs can be used to predict potential disease associations from various variable inputs.  
These previous efforts help to identify and define the research objectives for optimizing 
ANN performance and then using the network to predict chemical-disease associations. 
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III. Research Objectives 
From the analysis of the literature review, several areas of research became 
apparent that would attempt to solve the issues presented in Chapter 1.  The research 
objectives of this thesis are as follows: 
1) What chemical structural characteristics should be used to create a new 
chemical classification system capable of being used in identifying chemical-
disease associations?  The first problem addressed will be the creation of a 
new chemical classification system. Reviews of previous research efforts will 
be used to highlight potential chemical properties that could be successfully 
used to create a new numbering system. 
2) How can MATLAB ANN capabilities be used to connect chemicals to 
diseases using chemicals structural properties?  Before a predictive ANN can 
be created in MATLAB, it needs to be shown that the MATLAB ANN can 
properly analyze the input and output data of the new chemical classification 
system obtained from the CTD. Showing that the MATLAB ANN can be used 
for this purpose establishes the foundation needed to continue on to the next 
phase of research. 
3) What TVT ratio provides the best network performance?  Investigating the 
best TVT ratio to use with the chemical and disease data in the network is 
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important so that the network performs at the highest level possible. If a 
suboptimal TVT ratio is used, the predictability of the network will suffer. 
4) What training function provides the best network performance?  A proper 
training function used in the network is equally as important as a proper TVT 
ratio.  The training function establishes the algorithm the network will use to 
train the data and update the weights and biases of the network.  There are 
several training functions to choose from in the MATLAB ANN and each one 
trains the data differently. Determining the proper training ratio increases the 
prediction potential of the network. 
5) How can the network be used to predict diseases that are linked to uncurated 
chemicals?   The final step in addressing the problem statement is determining 
if the network can be used to accurately predict disease outputs. This will be 
done by creating an ANN with known chemical-disease relationship using 
curated chemical data from the CTD. Then, uncurated chemicals will be 
entered into the system and the outputs will be analyzed to see if the model 
can generate valid predictions. 
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IV. Methodology 
Overview 
 This chapter will discuss the methods used to acquire, test, and analyze the data in 
attempting to show that a predictive ANN model can be created to correlate chemicals to 
unknown disease associations.  The data source and required data information will be 
explained as well as how the ANN will be used to analyze the data.  The three 
simulations needed to complete the research will be addressed as well as how the output 
data will be analyzed to obtain the final results.  
Chemical Classification System 
A new numbering system was created that attempted to incorporate specific 
qualities of the chemical into the classification number while still ensuring that each 
chemical would have an individual and unique number.  From investigating previous 
research of quantitative structure activity relationships, several studies demonstrated that 
readily available physical properties of chemicals could be used to predict a chemical’s 
effect when used in an appropriate model (Schultz et al., 2002, Fang et al., 2001, Lipinski 
et al., 2012, Ren, 2002, Svetnik et al., 2003).  Using readily available chemical properties 
allows for a chemical classification system number to be created without extensive 
testing or data collecting.  
Three chemical traits that proved useful, particularly in a chemicals effect on 
estrogenicity, were molecular weight, hydrogen donors, and hydrogen acceptors (Lipinski 
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et al., 2012).  In addition to being successfully used in previous research, these three 
chemical traits are also fairly simple to obtain.  Without performing complex testing, the 
molecular weight can be easily calculated from the chemical formula while the hydrogen 
acceptors and donors are added up based on the number of lone pair electrons and atoms 
bonded to at least one hydrogen atom.  For example, the oxygen atom in water has one 
free pair of electrons so water has one hydrogen acceptor.  The oxygen atom in water is 
also connected to two hydrogen atoms so water has one hydrogen donor. 
The numbering system created gave each chemical a ten-digit number that was 
exclusive to that specific chemical.  The first six digits of the number correspond to the 
molecular weight of the chemical including two decimal places.  The seventh and eight 
digits represent the number of hydrogen acceptors and the ninth and tenth digits represent 
the number of hydrogen donors.  Figure 1 shows an example of how the new chemical 
classification number is created for water.  Water has a molecular weight of 18.015 
g/mol, 1 hydrogen acceptor, and 1 hydrogen donor.  Inputting these numbers into the new 
classification system, the new number generated for water is 0018020101. 
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Figure 1: New Chemical Classification Example 
The molecular weight in the classification number is assigned to the hundredths 
place to provide sufficient accuracy and uniqueness for identifying the chemical.  The 
number of hydrogen acceptors and hydrogen donors further reduce the possibility that 
two different chemicals would have the same classification number.  
Data 
The data used in the MATLAB simulations comes from the online CTD. The 
CTD is developed and maintained through a joint effort between North Carolina State 
University and Mount Desert Biological Laboratory and also receives financial support 
from the National Institute of Environmental Health Sciences. The primary goal of the 
CTD is to advance the understanding of the effects of environmental chemicals on human 
health through studying the relationships between chemicals, genes, and diseases. This 
online database is a collection of curated and uncurated data containing information for 
chemicals, genes, and diseases.  Curated data is data that has peer-reviewed, scientific 
research to prove existence of the data relationship (i.e. chemical-disease association).  
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Uncurated data does not have any literature showing interactions with other factors. The 
CTD contains over 800,000 chemical–gene associations, 12,400,000 gene-disease 
associations, and 1,300,000 chemical-disease associations with additional data and 
updates made weekly. Chemicals, genes, and diseases that are curated have been 
organized based on documented scientific research. Uncurated chemicals, genes, and 
diseases do not have the support of peer-reviewed research. While uncurated data do not 
have documentation to prove associations, the CTD does list possible associations 
through inferences. An inferred association between a chemical and a disease is 
established with a curated chemical-gene and gene-disease relationship. For example, 
acetone has a curated relationship with the catalase (CAT) gene and the CAT gene has 
been shown to affect asthma in humans.  There is no direct link between acetone and 
asthma but it can be inferred through the curated relationships with the CAT gene (Davis 
et al., 2013)  
The CTD website offers several organization and research functions that can be 
used to explore how the chemicals, genes, and diseases interact and related to one 
another. These functions allow users to research specific categories within the data and 
specify particular relationships of interest. In addition to the search functions, user can 
download entire sets of the database to use in simulations and research.  
Chemicals 
The chemicals used in the MATLAB ANN simulations were randomly chosen 
from the CTD.  As chemicals were selected, they were checked to make sure each 
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chemical was curated so that known disease associations existed to use in the network. 
Chemicals were also traced back to their most common ancestor chemical if they were a 
descendant.  Descendant chemicals were traced back to a common ancestor to ensure 
there was enough data to use in the simulations.  Once the ancestor chemicals were 
determined, the molecular weight, hydrogen acceptors, and hydrogen donors were 
determined and the new classification system number was generated for each chemical.  
Table 1 shows the list of chemicals used in the simulations, along with the classification 
number, chemical formula, and chemical structure diagram.  The chemical formulas and 
structure diagrams were included to show the diversity of the chemicals used.   
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Table 1: Chemical Information 
Chemical Name 
New 
Classification 
Number 
Molecular 
Formula Chemical Structure 
Acetone 0058080100 C3H6O 
 
Aciclovir 0225200804 C8H11N5O3 
 
Alprazolam 0308760300 C17H13ClN4 
 
Ammonium Sulfate 0132140402 H8N2O4S 
 
Aspirin 0180160401 C9H8O4 
 
Atenolol 0226340403 C14H22N2O3 
 
 21 
 
Azithromycin 0748981405 C38H72N2O12 
 
Benzene 0078120000 C6H6 
 
Benzyl Penicillin 0334390602 C16H18N2O4S 
 
Caffeine 0194190300 C8H10N4O2 
 
Candoxatril 0515640702 C29H41NO7 
 
Carbamazepine 0236270101 C15H12N2O 
 
Sodium Hydroxide 0039990101 HNaO 
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Chloramphenicol 0323130503 C11H12Cl2N2O5 
 
Cimetidine 0252340403 C10H16N6S 
 
Clonidine 0230090102 C9H9Cl2N3 
 
Copper Sulfate 0159610400 CuO4S 
 
Cyclosporine 1202611205 C62H111N11O12 
 
Desipramine 0266380201 C18H22N2 
 
Dexamethasone 0392460603 C22H29FO5 
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Diazepam 0284740200 C16H13ClN2O 
 
Diclofenac 0296150302 C14H11Cl2NO2 
 
Diltiazem-HCl 0414520600 C22H26N2O4S 
 
Doxorubicin 0543521206 C27H29NO11 
 
Enalaprilat 0376450602 C20H28N2O5 
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Erythromycin 0733931405 C37H67NO13 
 
Ethylene Glycol 0062070202 C2H6O2 
 
Famotidine 0337450804 C8H15N7O2S3 
 
Felodipine 0384250501 C18H19Cl2NO4 
 
Ferric Chloride 0162200000 Cl3F 
 
Fluorouracil 0130080302 C4H3FN2O2 
 
Flurbiprofen 0244260301 C15H13FO2 
 
Formaldehyde 0030030100 CH2O 
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Furosemide 0330740703 C12H11ClN2O5S 
 
Gabapentin 0171240302 C9H17NO2 
 
Glycerol 0092090303 C3H8O3 
 
Hydrobromic Acid 0080910000 BrH 
 
Hydrochloric Acid 0036460001 HCl 
 
Hydrochlorothiazide 0297740703 C7H8ClN3O4S2 
 
Hydrofluoric Acid 0020010101 FH 
 
Ibuprofen 0206280201 C13H16O2 
 
Imipramine 0280410200 C19H24N2 
 
Isopropyl Alcohol 0060100101 C3H8O 
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Itraconazole 0705630900 C35H38Cl2N8O4 
 
Ketoconazole 0531430600 C26H28Cl2N4O4 
 
Ketoprofen 0254280301 C16H14O3 
 
Labetalol-HCl 0328410404 C19H24N2O3 
 
Lisinopril 0405490704 C21H31N3O5 
 
Magnesium Sulfate 0120370400 MgO4S 
 
Mannitol 0182170606 C6H14O6 
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Methotrexate 0454441205 C20H22N8O5 
 
Metoprolol 0267360402 C15H25NO3 
 
Nadolol 0309400504 C17H27NO4 
 
Naloxone 0327370502 C19H21NO4 
 
Naproxen-sodium 0230260301 C14H14O3 
 
Nortriptylene-HCl 0263380101 C19H21NO4 
 
Omeprazole 0345420601 C17H19N3O3S 
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Phenytoin 0252270202 C15H12N2O2 
 
Piroxicam 0331350702 C15H13N3O4S 
 
Potassium Bromide 0119000100 BrK 
 
Potassium 
Permanganate 0158030400 MnO4K 
 
Prazosin 0383410801 C19H21N5O4 
 
Propranolol-HCl 0259350302 C16H21NO2 
 
Quinidine 0324430401 
 
C20H24N2O2 
 
 
Ranitidine-HCl 0314410702 C13H22N4O3S 
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Silver Nitrate 0169870300 AgNO3 
 
Sodium Thiosulfate 0158110400 Na2O3S2 
 
Tenidap 0320760402 C14H9ClN2O3S 
 
Terfenadine 0471690302 C32H41NO2 
 
Testosterone 0288430201 C19H28O2 
 
Trovafloxacin 0416361002 C20H15F3N4O3 
 
Valproic-acid 0144220201 C8H16O2 
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Vinblastine 0810971203 C46H58N4o9 
 
Zinc Chloride 0136290000 ZnCl2 
 
Ziprasidone 0412940501 C21H21ClN4OS 
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Diseases 
Due to the large number of diseases present in the CTD, the diseases were 
combined into 27 groups based on the classifications used in the CTD.  Rather than 
associating each chemical with every associated disease, the chemicals were related to 
the disease group that contained the actual associated disease.  Each disease group was 
assigned a number, 1-27, to represent that disease group in the network.  Table 2 shows 
the 27 diseases groups used in the network and the disease identification number assigned 
to each group. 
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Table 2: Disease Groupings 
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Artificial Neural Network 
     Figure 2 shows an illustration of how the ANN operated for the MATLAB 
simulations.  The ANN took the input and output data for each chemical-disease 
association and used the training function in the hidden layer to update the weights and 
biases in an attempt to find patterns and correlations between the input and output data.  
Based on the pre-determined values in the TVT ratio, the ANN would select the 
designated amount of data to train the network with.  After training, the ANN would then 
validate the network with the designated amount of data, and finally test the network with 
the remaining data.  In Figure 2, the three output categories (species, dummy variable, 
and disease) within the ANN represent the actual disease outputs obtained from the CTD.  
The outputs on the outside of the ANN represent the outputs generated by the ANN 
during the testing phase of each simulation.  The code used in the network simulations 
can be found in Appendix A. 
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Figure 2: Artificial Neural Network Example 
Input and Output Data 
Before running the network simulations in MATLAB, the data were first 
formatted to fit the ANN requirements as defined by the MATLAB user guide.  The input 
and actual associated output data from the CTD were entered into two matrices created in 
Microsoft Excel from which MATLAB was coded to retrieve the data.  The input data 
were entered into a matrix with three columns, one each for molecular weight, hydrogen 
acceptors, and hydrogen donors.  These three chemical characteristics were left as 
individual data points for the input data, rather than being entered in one column as the 
new classification number, to keep the size of the input and output matrices the same and 
reduce the use of dummy variables.  The output data were entered into a matrix the same 
size as the input data matrix with columns for species, dummy variable, and disease 
group.  Species were given numbers, similar to the disease groups, and the species and 
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their assigned numbers can be found in Table 3.  The species number is specifically 
related to the species that the chemical-disease association occurs in.  For example, 
acetone has a curated relationship with neoplasms (disease category 15) and this 
chemical-disease association occurs in humans.  A dummy variable was used in the 
output matrix to keep the matrix the same size as the input data matrix.  Zeros were 
entered for the dummy column values and the dummy column was not used in any of the 
results analysis. 
Table 3: Species Table 
 
The number of rows used for each chemical was determined by the number of 
disease groups the chemical was associated with.  For example, acetone was associated 
with six diseases groups so it used six rows in both the input and output matrices.  The 
actual input and output data used for acetone can be seen in Table 4.  The six rows used 
in the input matrix all contained the same molecular weight, hydrogen acceptor, and 
hydrogen donor data.  Each of the six rows in the output matrix corresponded to one of 
the associated disease groups and subsequent related species.  The complete input and 
output matrices can be found in Appendix B. 
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Table 4: Acetone Input and Output Matrices 
Inputs  Outputs 
Molecular 
Weight 
Hydrogen 
Acceptors 
Hydrogen 
Donors   Species Dummy 
Disease 
Group 
58.08 1 1  1 0 9 
58.08 1 1  1 0 12 
58.08 1 1  1 0 15 
58.08 1 1  1 0 16 
58.08 1 1  1 0 17 
58.08 1 1   1 0 25 
Simulations 
Three phases of simulations were used to test the ANN.  The first phase of 
simulation was accomplished to demonstrate that the MATLAB ANN could be used to 
analyze the chemical and disease data and find appropriate correlations.  Initially, 20 
chemicals were chosen from the CTD and the input and output matrices were created 
based on the chemical characteristics and associated species and diseases groups.  This 
simulation used the basic MATLAB ANN code formatted with a TVT ratio of 80-10-10 
percent and the default training function.  Results from the first phase simulation can be 
found in Figures 3-9 in Chapter 4. 
The second phase of simulations involved testing different TVT ratios and 
training functions on the network which provided the best network performance.  To do 
this, an additional 55 chemicals were chosen at random from the CTD and the 
appropriate chemical, species, and disease group data were added to the input and output 
matrices.   First, five different TVT ratios were tested in the network using the default 
training function: 50-25-25, 60-20-20, 70-15-15, 80-10-10, and 90-5-5 percent.  These 
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five ratios were chosen so that an appropriate TVT ratio could be chosen while also 
highlighting how the different ratios affect the ANN.  Next, each of the 15 training 
functions was tested in the network using the 70-15-15 percent TVT ratio.  The 
MATLAB training functions used are preprogrammed functions built within MATLAB.  
All of the functions operated in a feedforward network with backpropagation.  A feed 
forward network is where the data is passed through the hidden layer in a single direction 
from the input side to the output side.  The backpropagation step involves going back to 
adjust the weights and biases in the hidden layer after comparing the actual outputs to the 
ANN derived outputs.  Each of the training functions are based off of a gradient descent 
algorithm where the training function attempts to decrease the error in the network by 
adjusting the weights and biases after each network iteration.  The results from the 
different training ratios indicated that the trainlm, Levenberg-Marquardt 
backpropagation, function generated the best network performance. 
The third phase of simulations involved inputting uncurated chemical data into 
the network that had no known disease associations to see what diseases the network 
would predict.  To accomplish this, a network simulation was first run with the original 
75 chemicals using the 70-15-15 percent TVT ratio and trainlm training function.  The 
70-15-15 percent TV ratio and trainlm training function provided the best network 
performance in the second phase of simulations.  This established the correlations, 
weights, and biases for the network to use on the uncurated chemicals.  Then the data for 
three uncurated chemicals were run through the network 10 times and the network-
derived disease output results for each trial were recorded.  Each uncurated chemical was 
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input into the network 10 times to allow multiple disease association predictions to occur 
in the event that a chemical was associated to more than one disease.  The network 
outputs generated had to be rounded to directly correlate them to the whole number 
designators assigned to each disease group.  Several network outputs produced the same 
disease group more than once for a given input chemical.  For duplicate disease 
predictions, these outputs were consolidated into one output.  The derived disease outputs 
were then compared to research literature to see if the network predictions were correct.       
Analysis and Results 
Once the simulations were complete in MATLAB, all of the output data was 
copied into Microsoft Excel for analysis.  Analyzing the first phase of simulations was 
done simply by reviewing the output plots and figures generated by MATLAB at the 
completion of the simulation.  The analyses of the phase two simulations used Microsoft 
Excel to plot and chart the output data from MATLAB.  The primary graph used plotted 
the actual diseases values versus the ANN derived disease values.  When the network 
produced accurate output results, the plot would follow a linear, one-to-one slope on the 
graph.  Excel was also used to calculate the coefficient of determination (R2) values to 
see how well the data followed a linear progression.  The analysis also compared the 
different TVT ratios and training functions based on network parameter values to 
determine which ratio or function provided the best network performance.  Additionally, 
the effects of undertraining and overtraining the network on ANN derived disease values 
were taken into account.  The third phase of simulations was primarily analyzed by 
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comparing the ANN derived disease values to research literature in an effort to show that 
the network had some predictive capability for uncurated chemicals. 
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V. Analysis and Results 
ANN Training Results 
The following figures were generated from a typical MATLAB ANN simulation 
using the default training settings and a TVT ratio of 80-10-10 percent.  They show 
typical results seen during the first phase of simulations when the initial group on 20 
chemicals was used in the ANN. 
Figure 3 shows a typical MATLAB training session for an ANN. The neural 
network diagram shows a pictorial of how the network will function, given the 
requirements established in the network code. At the top of the figure, the diagrams 
shows the number of inputs and outputs being used and the number of hidden layers. The 
data division and derivative algorithms are preset within MATLAB and these default 
settings were used for the various simulations. The training algorithm defines the training 
function used in the network, which dictates how the data will be trained.  The 
performance algorithm measures how well the network is operating during training. The 
training and performance algorithms can be changed separately; however, a default 
performance algorithm will be chosen based on the training algorithm if a specific 
performance algorithm is not defined.  
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Figure 3: Typical MATLAB ANN Training Session 
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The progress portion of Figure 3 shows the network performance criteria that 
provide information on the progress of network training. As the simulation progresses, 
these performance criteria update to show the current status of the training. The epochs 
show the number of iterations over the course of the simulation. Performance shows how 
accurately the network is generating output values compared to the actual output values. 
The performance values are the mean-squared error of the network so lower performance 
values indicate higher network training performance. The gradient is an optimization 
algorithm that measures the adjustments made to the network in relation to the network 
performance during each epoch. If a network is performing well, smaller adjustments are 
needed so the gradient will be smaller. Likewise, if a network is performing poorly, 
larger adjustments are needed to attempt to improve performance so the gradient will be 
larger. The mu value shows how much the network is required to change the weights and 
biases placed on the input data to achieve accurate output results. The weights and biases 
are used to adjust and determine how the input data is used when training the network. If 
the network finds some input data provides better performance than other data, it will 
place more weight on the data that increases performance. When a network has high mu 
values during training, the network is struggling to find weight and bias values that work 
for the data set. The validation checks show the number of iterations where the 
simulation’s validation performance does not decrease. After the network is trained, it is 
validated to ensure the training was successful.  
All of these performance criteria have upper and lower boundaries and when the 
appropriate boundary of one of the criteria is reached, the simulation is terminated. 
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Performance and gradient will both terminate the simulation when they reach their lower 
limit values. If performance or gradient terminate the simulation, this generally indicates 
a successful training because lower performance and gradient values correlate to higher 
network performance. Epochs, mu and validation checks will terminate the simulation 
when they reach their upper limits. When the number of epochs terminates the 
simulation, the network has used all of the allotted iterations before the performance or 
gradient have reached an acceptable level. Network termination due to a high mu value 
indicates that the network failed to find appropriate weight and bias values. Terminating 
for a high number of validation checks indicates the network did not train well because it 
was unable to be validated. Time is the only criterion that does not terminate a simulation 
as it is simply meant to track how long the simulation takes. Once the network training is 
complete, there are several figures that MATLAB can create which provide additional 
information about the network simulation.  Figures 4-9 show the different plots that can 
be generated by MATLAB after the network simulations.  Additional training sessions 
and supporting figures can be found in Appendix C. 
Figure 4 shows a typical MATLAB-generated plot of the actual disease numbers 
plotted against the ANN derived disease. When the plot shows a straight, positive, one to 
one slope, the ANN derived disease number is close to the actual disease number. The 
straight, one to one slope seen in the figure suggests that the network was able to 
correctly derive the appropriate disease number for each chemical.  
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Figure 4: Typical MATLAB Actual Disease versus ANN Derived Disease Outputs 
Plot 
Figures 5 and 6 show the performance (i.e. mean squared error) of the ANN 
simulation discussed from Figure 3. The two plots look identical because the network 
used the mean squared error to judge the performance of the network as it was trained. 
The lower the performance value, or mean squared error value, the better the network is 
performing because they is less variation between the actual disease groups numbers and 
the ANN derived disease group numbers. The figures show the performance of the 
network for each epoch during the simulation. During the simulation, the training 
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performance decreases until epoch 11 where the performance values plateau.  In Figure 5, 
the validation and test curves follow the same path as the train performance curve.  
 
 
Figure 5: Typical MATLAB ANN Performance Plot 
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Figure 6: Typical MATLAB ANN Mean Squared Error Plot 
Figure 7 shows a typical regression plot produced from an ANN network 
simulation. Similar to Figure 4, a positive, straight, one to one slope is desired to show 
that the ANN derived disease numbers match the actual disease numbers. In this plot, the 
target, x-axis, values represent the actual disease numbers and the output, y-axis, values 
represent the ANN derived disease numbers. The training R-value shows how closely the 
derived numbers compare to the actual numbers. An R-value of one would indicate a 
perfect match of the derived to the actual disease number so the higher the R-value, the 
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more accurate the Ann derived disease numbers are. The high R-value of 0.9985 for this 
simulation corresponds to the straight, one to one slope seen in the graph. 
 
Figure 7: Typical MATLAB ANN Regression Plot 
Figure 8 shows how the gradient, mu, and number of validation checks values 
fluctuation during the course of the network simulation. The decreasing gradient and mu 
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values both indicate the network was performing well. The validation checks remaining 
at zero also indicated that the network training was performing well. In this simulation, 
from Figure 3, the gradient parameter was the termination factor because it reached its 
lower limit. 
 
Figure 8: Typical MATLAB ANN Training States 
Figure 9 shows how the gradient, mu, and number of validation checks values 
fluctuation during the course of the network simulation. The decreasing gradient and mu 
values both indicate the network was performing well. The validation checks remaining 
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at zero also indicated that the network training was performing well. In this simulation, 
from Figure 3, the gradient parameter was the termination factor because it reached its 
lower limit. 
 
 
Figure 9: Typical MATLAB ANN Error Histogram Plot 
After the ANN was shown to be capable of fitting chemical and disease input and 
output data in the model.  The TVT ratios and training functions were tested in the 
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second phase of simulations.  Using the TVT ratio as an independent variable yields a 
wide range of training performance parameter values.  Table 5 shows the effects that 
different TVT ratios can have on the network performance criteria.  From the data 
collected, the 70-15-15 TVT ratio provided the best overall performance for the training 
of the network.  The higher average number of epochs associated with the 70-15-15 TVT 
ratio shows that this ratio allowed the network more opportunity to improve with more 
simulation iterations than the other ratios.  While the 60-20-20 TV ratio had a lower 
average performance value, it had a higher average mu value and a higher average 
number of validation checks indicating that the 60-20-20 ratio did not adequately 
establish proper weight values and could not continue to improve performance of the 
network.  Although the 70-15-15 TVT ratio had the highest average gradient value, it had 
the lowest average mu and lowest number of validation checks of the five TVT ratios.  
Table 5 shows that over the five network training criteria, the 70-15-15 TVT ratio 
provides the best overall performance with that data. 
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Table 5: The Effect of TVT Ratio on Network Training Statistics 
Ratio 
  
Network Training Parameters 
Epochs Time Performance Gradient Mu 
Validation 
Checks 
50-25-25 
Minimum 3 37.75 3.929 1.174 2.00E-07 1 
Maximum 8 208.05 92.510 642.100 2.00E+04 6 
Average 4.4 90.07 37.277 192.282 2.91E+03 3 
60-20-20 
Minimum 4 69.48 0.380 0.213 6.02E-06 4 
Maximum 12 219.66 96.450 993.201 2.40E+05 6 
Average 7.8 146.72 20.792 310.266 6.92E+04 5.2 
70-15-15 
Minimum 10 154.85 0.177 0.000 8.20E-07 0 
Maximum 14 256.19 90.037 2326.863 2.40E+02 0 
Average 11.6 195.68 24.871 422.535 2.00E+01 0 
80-10-10 
Minimum 6 92.27 16.926 0.000 6.00E-04 0 
Maximum 19 276.79 95.657 810.218 2.01E+04 0 
Average 9.8 150.64 46.503 172.010 2.12E+03 0 
90-5-5 
Minimum 2 32.45 0.000 0.001 4.02E-04 0 
Maximum 9 192.81 94.892 512.904 2.20E+05 6 
Average 4.4 101.67 42.661 120.958 4.69E+03 3.4 
 
 
Figure 10 shows the R2-values for the five different TVT ratios used in network 
simulations. The 70-15-15 percent ratio clearly provides the best fit for the data with a 
high R-value of nearly one. The 80-10-10 percent ratio also performs well but has a lower 
R2-value than the 70-15-15 percent ratio. The other ratios have low R2-values and the 
plots of the ANN derived disease numbers versus actual disease numbers show the 
inaccuracy of those models. Individual plots for each of the TVT ratios used can be found 
in Appendix D. 
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Figure 10: TVT Ratio Effect on the Coefficient of Determination 
In addition to TVT ratios, altering the training functions used to train the network 
can also affect network performance. Table 6 shows the effects that different training 
functions have on the network performance criteria. When conducting simulations with 
the different training functions, the 70-15-15 TV ratio was used to organize the data as it 
was determined to provide the best performance with the network. Explanations for all of 
the training functions used can be found in Appendix E.  From the data collected in the 
simulations, the trainlm provided the best overall training performance for the 
simulations. Because not all of the training functions used gradient, mu or validations 
checks as performance parameters, epochs, time and performance were the main 
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parameters used to compare the different functions. The maximum number of epochs was 
used to terminate the simulations for 10 of the 15 training functions used in the network.  
While the trainlm training function did not have the lowest performance value, its 
simulations were terminated due to the gradient reaching the lower limit indicating high 
network performance. Training function traingscg had a lower performance parameter 
but also had a lower R-value when the actual and ANN derived disease numbers were 
plotted.  It should also be noted that training functions with shorter network run times 
generally performed worse than functions with longer run times.  
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Table 6: The Effects of Training Functions on Network Training Statistics 
Function   Performance Parameters   Epochs Time Performance Gradient Mu Validation Checks 
trainb 
Minimum 1000 32.94 85.55 - - 0 
Maximum 1000 47.24 102.43 - - 0 
Average 1000 38.27 93.48 - - 0 
trainc 
Minimum 1000 47.95 65.06 - - - 
Maximum 1000 306.49 101.05 - - - 
Average 1000 214.66 79.73 - - - 
traincgb 
Minimum 3 0.18 64.27 2.68 - 0 
Maximum 13 0.22 88.41 416.71 - 0 
Average 9 0.20 71.86 260.10 - 0 
traincgf 
Minimum 101 0.75 40.37 1.07 - 0 
Maximum 659 4.90 88.26 457.27 - 0 
Average 290 2.17 47.37 72.29 - 0 
traincgp 
Minimum 5 0.26 55.00 1.68 - 0 
Maximum 161 1.62 89.20 361.27 - 0 
Average 88 0.94 59.85 38.10 - 0 
traingd 
Minimum 1000 2.85 48.12 0.93 - 0 
Maximum 1000 2.86 100.66 229.21 - 0 
Average 1000 2.86 61.70 2.30 - 0 
traingda 
Minimum 1000 2.99 68.21 195.53 - 0 
Maximum 1000 3.30 146.91 408.98 - 0 
Average 1000 3.18 73.10 329.39 - 0 
traingdm 
Minimum 1000 3.11 48.10 0.94 - 0 
Maximum 1000 3.56 104.42 576.00 - 0 
Average 1000 3.27 84.38 2.55 - 0 
traindgx 
Minimum 1000 3.25 78.80 3.17 - 0 
Maximum 1000 3.27 95.30 602.00 - 0 
Average 1000 3.59 80.53 133.58 - 0 
trainlm 
Minimum 10 154.85 0.18 0.00 0.00 0 
Maximum 14 256.19 91.97 2143.91 400.00 0 
Average 13 219.36 27.91 394.93 33.25 0 
trainoss 
Minimum 1000 6.35 0.34 0.00 - 0 
Maximum 1000 10.19 99.07 550.00 - 0 
Average 1000 7.65 36.37 2.49 - 0 
trainr 
Minimum 1000 52.66 64.00 - - - 
Maximum 1000 87.99 101.85 - - - 
Average 1000 64.48 79.43 - - - 
trainrp 
Minimum 45 0.27 42.00 0.00 - 0 
Maximum 49 0.35 99.69 524.00 - 0 
Average 47 0.31 47.37 5.53 - 0 
trains 
Minimum 1000 21.25 83.90 - - - 
Maximum 1000 25.84 100.76 - - - 
Average 1000 23.35 91.88 - - - 
trainscg 
Minimum 1000 4.60 0.44 0.12 - 0 
Maximum 1000 7.86 95.46 545.60 - 0 
Average 1000 5.87 25.54 9.57 - 0 
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Figure 11 shows the R2-values for each of the training functions used in the 
network simulations. Several of the training functions had good R2-values, above 0.7, but 
the majority fell around or below 0.5 indicating most training functions did not have a 
good fit with the data. The Trainlm function had the highest R2-value of 0.999.  Trainrp 
also had an R2-value of 0.999 but the slope of the line 0.5:1, not 1:1.  Trainscg had the 
second highest R-value of 0.9769 but the ANN derived disease number versus actual 
disease number plot was not as linear as Trainlm. Plots for all of the training functions 
can be found in the Appendix. 
 
 
Figure 11: Training Function Effect on the Coefficient of Determination 
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ANN Model Performance for Curated Chemicals 
Utilizing curated chemicals from the CTD allowed various network models to be 
created testing different TVT ratios. The actual disease number is known when using 
curated chemicals so the ANN derived disease numbers can easily be compared to the 
actual values to determine how well the network is performing. 
 Effect of Training Ratio on Model-Predicted Disease 
Figure 12 shows typical actual disease number versus ANN derived disease 
number plots for each of the five TVT ratios used. For the simulations shown, default 
training functions and parameters were used in the network. The graph also includes a 
one-to-one slope line to easily compare the different simulations results to the desired 
values. As discussed earlier, the 70-15-15 percent TVT ratio generated the best network 
performance. Comparing the different TVT ratio plots, it is evident that the other ratios 
do not produce the same performance as the 70-15-15 percent ratio and are unable to 
accurately generate ANN derived disease numbers.
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Figure 12 also highlights three structurally different chemicals used in the 
network simulations showing how their ANN derived disease numbers compare to their 
actual disease numbers when using the 70-15-15 percent TVT ratio.  Two important 
details about the network can be seen when examining the three highlighted chemicals.  
First, the network is able to take inputs from different chemicals and correctly match it to 
a single disease category.  Potassium permanganate and ethylene glycol can both be 
correctly linked to disease group five and ethylene glycol and candoxatril can both be 
correctly linked to disease category 16.  In addition to matching multiple chemicals to 
one disease category, the network also correctly took inputs from a single chemical and 
linked it to multiple diseases that it is related to.  Both ethylene glycol and candoxatril are 
shown to correctly have associations with multiple disease categories.    
Chemical Trends for Undertrained Model Simulations 
Figure 13 shows the effects of using an undertrained network on the ANN derived 
disease number using the average of five trials of simulation data.  Nearly all of the ANN 
derived disease numbers fall below the one to one slope line which correlates to the low 
R2-value seen in Figure 4.8.  For every disease associated with each of the three 
chemicals, the ANN derived disease number was lower than the actual value. The 
network was unable to derive the same disease number for multiple chemicals that were 
linked to the same disease. When the network did not have enough data available to 
properly train with, the performance of the network suffered and produced inaccurate 
results.
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Figure 13 also shows the three chemicals highlighted in Figure 12 to display how 
the network derives disease numbers for them when not provided with enough training 
data.  When examining the three chemical’s ANN derived disease numbers, it is evident 
that the undertrained network is not able to predict the correct values.  When more than 
one chemical is linked to the same disease, the network is unable to predict the same 
disease for the multiple chemicals.  Potassium permanganate and ethylene glycol should 
both be related to disease category 5 but the network predicts values near 3.5 and 1.5 
respectively.  Not providing enough data for the network to train with negatively affects 
the overall performance of the network. 
Occasionally, less than 0.5% of the time, the network will generate a disease 
value close to the actual value, but this does not occur on a consistent basis.  It is also not 
consistent for a certain chemical or disease.  For example, in one simulation, the network 
generated a disease number of 14.2692 for formaldehyde.  Formaldehyde is related to 
disease category 15 (neoplasms) so this is a difference of 4.9%.  Formaldehyde is also 
related to 23 other disease groups and the closest network generated disease number out 
of the remaining 23 was 25.6% off the actual number.  Out of the five simulations run 
with the network, this was also the only time a number within 5% of 15 was generated for 
formaldehyde.  
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Chemical Trends for Overtrained Model Simulations 
Figure 14 shows the effects of using an overtrained network on the ANN derived 
disease number.  The results shown in Figure 14were obtained using a TVT ratio of 90-5-
5 percent and the default network training settings.  Similar to the results seen in Figure 
13, the network was unable to generated correct disease numbers and nearly all of the 
generated values fell below the one to one slope line.  The overtrained network saw 
similar failures when choosing disease number for multiple chemicals associated with 
one disease.  Potassium permanganate and ethylene glycol should have had a disease 
number of five generated by the network, but instead values of 2.75 and 1.75 were 
generated for the two chemicals, respectively.    
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ANN Model Performance for Uncurated Chemicals 
  Three uncurated chemicals from the CTD were selected to be tested by the ANN 
using a 70-15-15 TVT ratio and the trainlm training function.  While these chemicals 
were uncurated in the database, there is research to suggest that they are related to certain 
diseases.  Testing the network with these chemicals gives the ability to determine how 
well the model can predict chemical-disease associations. 
Figure 15 shows the network results when the uncurated chemical cystaphos was 
input into the network. From the 10 inputs, the network generated seven possible disease 
output numbers.  Of the seven predicted outputs, neoplasm was generated by the network 
and had literature from previous research to support this network prediction. For 
example, the Defense Threat Reduction Agency (DTRA) in 2006 conducted a review of 
previous Soviet Union research involving biological actions of neutron radiobiology. 
DTRA discovered several trials where animals were injected with cystaphos or cystaphos 
mixed with other chemicals. These trials included results that showed cystaphos was 
capable of protecting the intestinal system in mice from unwanted radiation damage 
(Defense Threat Reduction Agency, 2006).  In addition to the DTRA report, Barkaia et 
al. conducted research in 1989 involving cystaphos as an adjuvant in cancer treatment. 
Using mice, guinea pigs, monkeys, they injected the animals with cystaphos combined 
with sodium nitrite and mexamine after irradiating them with Cs-137 gamma rays. 
Barkaia et al. then monitored the radiation sickness exhibited by the animals and repeated 
the cystaphos solution injections to see if the radiation sickness lessened. From their 
experiments, they found that with repeated injections, the cystaphos solution helped to 
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protect healthy cells in the bone marrow, spleen, and intestine of the test animals (Barkaia 
et al., 1989).  The findings of Barkaia et al. mimic those mentioned in the DTRA report 
in that cystaphos appears to reduce the harmful effects of radiation and protect the 
intestinal system in mice. The results presented from these two studies support the 
network model prediction that cystaphos is linked to neoplasms.  This identified potential 
link does not indicate that cystaphos causes cancer, but rather it is connected to it in ways 
that are not fully understood.  The peer-reviewed literature does not contain studies that 
have examined the connection between cystaphos and any of the other predicted diseases. 
 
 
Figure 15: MATLAB ANN Derived Diseases for NCC Cystaphos 
Figure 16 shows the network results when the uncurated chemical 3,5-dibromo-2-
(2,4-dibromophenoxy)phenol (6-HO-BDE-47) was input into the network. From the 10 
inputs, the network generated nine possible disease output numbers with nervous system 
diseases being supported by previous research. Hendriks et al., 2010 studied the use of 
polybrominated diphenyl ethers (PDE) to stimulate nicotinic acetylcholine (nACh) and 
GABA(A) receptors on neurons in the brain.  Hendriks et al. took several PDEs, 
including 6-HO-BDE-47, and conducted tests investigating their affects on the nACH and 
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GABA(A) receptors. Their findings documented that 6-HO-BDE-47 was an antagonist to 
the nACH receptors yet acted as an agonist to GABA(A) receptors. The results showing 
that 6-HO-BDE-47 can be linked to nervous systems diseases from the work of Hendriks 
et al. supports the same prediction generated by the ANN model.  In addition to being 
related to nervous system diseases, there is also literature to support a possible connection 
to endocrine diseases. The network model did not predict endocrine diseases but an 
investigation conducted by Cao et al., 2010 indicates that this may be a possibility. Cao et 
al. took PDEs that were known to cause thyroid hormone disruption and tested to see if 
they bind to hormone transport proteins. Their results showed that 6-OH-PDE-47 had an 
affinity to binding with the thyroid hormone transport protein which could cause 
endocrine system problems.  Although the network predictions parallel the findings of 
Hendriks et al. and Cao et al., the model is only able to potentially link 6-OH-PDE-47 to 
nervous system and endocrine system diseases.  It does not indicated that 6-OH-PDE-47 
directly causes these diseases.  The peer-reviewed literature does not contain studies that 
have examined the connection between 6-HO-PDE-47 and any of the other predicted 
diseases. 
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Figure 16: MATLAB ANN Derived Diseases for NCC 6-HO-BDE-47 
Figure 17 shows the network results when the uncurated chemical 4,4’-
diiodobiphenyl (DIB) was input into the network. Seven output predictions were 
generated from the 10 inputs and endocrine system diseases had literature so support the 
network’s prediction. Yomada-Okabe et al., 2005 published research findings suggesting 
DIB affected thyroid hormone receptors by inhibiting gene expression. From their work, 
Yomada-Okabe et al. concluded that DIB affects the luciferase gene by enhancing the 
expression of it. Mediation of the luciferasse gene has been documented to act as an 
endocrine disruptor in animals and humans. This relationship indicates that DIB could be 
a potential source of endocrine disease as predicted by the model.  The peer-reviewed 
literature does not contain studies that have examined the connection between DIB and 
any of the other predicted diseases. 
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Figure 17: MATLAB ANN Derived Diseases for NCC 4,4'-diiodobiphenyl 
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VI. Conclusions and Recommendations 
Research Conclusions 
The conclusions from this research are as follows:  
1) A new chemical classification system was created to identify chemicals with a 
unique number based on structural characteristics of the chemical.  This new 
system facilitates the analysis of relationships between chemicals and 
diseases.  While the use of molecular weight, hydrogen acceptors, and 
hydrogen donors proved sufficient for creating the classification system that is 
able to be used in a predictive ANN, the ANN model results do not prove that 
these three variables provide the best performance results for predicting 
chemical-disease associations.  Other chemical characteristics may provide 
equal or better results.   
2) Artificial neural networks were successfully employed to associated chemicals 
and diseases. Initial simulations with TVT ratios of 80-10-10 percent 
produced coefficients of determination equal to 0.99. The ANN derived 
diseases were predicted using inputs that were formatted according to the new 
chemical classification system. 
3) The TVT ratio of 70-15-15 percent provided the best network performance 
when compared to other TVT ratios.  When compared to the other ratios 
tested in the network, the 70-15-15 percent TVT had the lowest performance 
values, or lowest error values, for ratios that produced network with zero 
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validation checks.  The lack of validation checks shows that the ANN was 
able to properly train the data.  Additionally, the 70-15-15 percent ratio had 
the highest R2 value (0.99) of the TVT ratios indicating it has a greater 
likelihood of accurately predicting disease output values.   
4)  The trainlm (Levenberg-Marquardt backpropagation) function provided the 
best network performance. The trainlm function had an R2-value of 0.99 and a 
one-to-one slope on the actual disease number versus ANN derived disease 
number plot. The trainrp and trainscg functions also produce good results with 
R2-values of 0.99 and 0.976 respectively; however, the trainrp function results 
did not follow a one-to-one linear slope and the trainscg function did not 
produce linear results.  The high R2 value indicates that the trainlm function 
has a greater chance of correctly predicting disease output values. 
5)  The ANN has potential to predict chemical-disease associations that are not 
yet curated.  Cystaphos was correlated to neoplasms and two independent 
literature sources supported the ANN prediction.  The ANN predicted that 
3,5-dibromo-2-(2,4-dibromophenoxy)phenol (6-HO-BDE-47) was associated 
with nervous system diseases and a research documentation supported this 
finding.  A separate literature source concluded that 6-HO-BDE-47 was also 
linked to endocrine diseases but the ANN failed to make that connection.  
4,4’-diiodobiphenyl (DIB) was correctly matched to endocrine disease and 
supported by an independent research report.  The ANN has demonstrated the 
potential to predict disease-associations for new chemicals and to guide 
research for existing chemicals that require toxicological testing.   
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Recommendations for Future Research 
Future research should carry out the following activities: 
1) Laboratory testing of chemical-disease associations that are predicted by the 
ANN model presented in this thesis, followed by possible refinements or 
modifications to the new chemical classification system. This should be 
carried out for both curated and uncurated chemicals.  One possibility would 
be to analyze chemicals that were grandfathered into the Toxic Substances 
Control Act inventory whose chemical-disease associations are unknown.  
2) Developing an ANN that correlates chemical-gene expression associations in 
order to develop a tool that provides insight into the mechanisms that cause 
(or prevent) disease. 
3) Testing of additional factors in the ANN to produce a more accurate model for 
correlating chemicals, genes, and diseases.  Utilized a loop function to 
iteratively step through every possible TVT ratio combination may discover a 
more optimal ratio to use in the network.  Additionally, testing transfer 
functions within the ANN hidden layer or adding additional hidden layers has 
the potential to show increased network predictive performance as well.
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Appendix A: MATLAB ANN Code 
1 % This code is used for the thesis work conducted by Capt Brouch 
2 % This code relates chemical input data to species and disease output data 
3 % This code is based on the sample input-output fitting network in the MATLAB ANN Guide 
4 % The script was last revised on 22 Jan 2014 by Capt Brouch 
5 % The format for the input matrix is: ['Molecular Weight' 'Hydrogen Acceptors' 'Hydrogen Donors'] 
6 % The format for the output matrix is: ['Species' 'Dummy Variable' 'Disease'] 
7 % The format for the input1 matrix is: ['Molecular Weight' 'Hydrogen Acceptors' 'Hydrogen Donors'] 
8 % The input1 matrix contains uncurated chemical data used to predict disease outputs 
9 
10- tstart = clock; 
11 
12- A = zeros(1173,3); 
13- B = zeros(1173,3); 
14- C = zeros(1173,3); 
15 
16- A(:,1) = xlsread('J:\Brouch\Brouch Thesis\Excel Files\Brouch Thesis ANN Data.xls','Input-Output Tables','b2:b1174'); 
17- A(:,2) = xlsread('J:\Brouch\Brouch Thesis\Excel Files\Brouch Thesis ANN Data.xls','Input-Output Tables','c2:c1174'); 
18- A(:,3) = xlsread('J:\Brouch\Brouch Thesis\Excel Files\Brouch Thesis ANN Data.xls','Input-Output Tables','d2:d1174'); 
19- B(:,1) = xlsread('J:\Brouch\Brouch Thesis\Excel Files\Brouch Thesis ANN Data.xls','Input-Output Tables','e2:e1174'); 
20- B(:,3) = xlsread('J:\Brouch\Brouch Thesis\Excel Files\Brouch Thesis ANN Data.xls','Input-Output Tables','g2:g1174'); 
21- C(:,1) = xlsread('J:\Brouch\Brouch Thesis\Excel Files\Brouch Thesis ANN Data.xls','Uncurated','c3:c1175'); 
22- C(:,2) = xlsread('J:\Brouch\Brouch Thesis\Excel Files\Brouch Thesis ANN Data.xls','Uncurated','d3:d1175'); 
23- C(:,3) = xlsread('J:\Brouch\Brouch Thesis\Excel Files\Brouch Thesis ANN Data.xls','Uncurated','e3:e1175'); 
24 
25- inputs = A; 
26- targets = B; 
27- inputs1 = C; 
28- % the targets matrix is the same as the output matrix 
29 
30 % preallocate the plotting matrix (PM) 
31- PM = zeros(1173,5); 
32 
33 % the variable is interest is vv - this is the column number in the target matrix 
34- vv = 3; 
35 
36- countt = 1; 
37 
38- for count = 1:1:5 
39 % Create a Fitting Network 
40- hiddenLayerSize = 1; 
41- net = fitnet(hiddenLayerSize); 
42 % Set up Division of Data for Training, Validation, Testing 
43- net.divideParam.trainRatio = 70/100; 
44- net.divideParam.valRatio = 15/100; 
45- net.divideParam.testRatio = 15/100; 
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46 % Train the Network 
47- [net,tr] = trainlm(net,inputs,targets); 
48 % Test the Network 
49- outputs = net(inputs); 
50- errors = gsubtract(outputs,targets); 
51- performance = perform(net,targets,outputs); 
52 % View the Network 
53 % view(net) 
54 % plotperf(tr) 
55 
56- Outputs = net(inputs); 
57 % trOut = Outputs(tr.trainInd); 
58 % vOut = Outputs(tr.valInd); 
59 % tsOut = Outputs(tr.testInd); 
60 % trTarg = Outputs(tr.trainInd); 
61 % vTarg = targets(tr.valInd); 
62 % tsTarg = targets(tr.testInd); 
63 % figure (98) 
64 % plotregression(trTarg,trOut,'Train',vTarg,vOut,'Validation',tsTarg,tsOut,'Testing'); 
65 
66- PM(:,countt) = Outputs(:,vv); 
67- countt = countt +1; 
68- end 
69 
70- figure(1) 
71 %plot(targets(:,vv),PM(:,1),'ro') 
72 %plot(targets(:,vv),PM(:,1),'ro',targets(:,vv),PM(:,2),'go',targets(:,vv),PM(:,3),'ko', targets(:,vv),PM(:,4),'m--', 
 targets(:,vv),PM(:,5),'k-.') 
73- title('The relationship between actual and predicted diseases, version 1') 
74- xlabel('Actual Disease Number') 
75- ylabel('ANN-Derived Disease Number') 
76 
77- tstop = clock; 
78- runtime = etime (tstop,tstart)/60; 
79- disp('length of run in minutes:') 
80- disp(runtime) 
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This MATLAB code was used to set up and run the various ANN simulations 
discussed in the paper.  The first eight lines of code explain what the code provide some 
background information about what the code is being used for and how the input and 
output data is organized.  Line 10 begins a clock to track how long the ANN simulations 
take to complete.  Lines 12-14 create matrices for the input and output data obtain from 
Microsoft Excel spreadsheets.  Lines 15-22 dictate where MATLAB fill find the data 
needed for the input and output matrices.  Lines 16-18 and 19-20 state the data needed for 
the input and output matrices, respectively.  Lines 21-23 identify the uncurated chemical 
data used to generate the ANN derived disease predictions.  Lines 25-27 define the input, 
output, and output1 matrices created in lines 12-14.  Line 31 creates the plotting matrix 
where the ANN derive diseases values will be saved.  In this code, the matrix is created 
with five columns so the five simulations can be run back to back.  Line 34 designates the 
variable of interest to be saved in the plotting matrix.  For this code, the variable of the 
interest is the third column in the target matrix: disease.  Lines 38-68 control and run the 
actual ANN.  Line 38 establishes how many simulations the network will run.  For this 
code, 5 simulations are run to match the number of columns in the plotting matrix.  Line 
40 controls the number of hidden layers the network used.  Lines 43-45 control how the 
network splits up the data according to the TVT ratio being used in the simulation.  Line 
47 designates the training function being used in the network.  Line 56 establishes what 
input data the network will use to generate the ANN derive disease outputs.  Lines 66-68 
tell the network to stop running simulations when it reaches the predetermined maximum 
number established in line 38.  Lines 70-75 generate the actual disease number versus 
ANN derived disease number plot once the network simulations are complete.  Lines 77-
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80 stop the clock that was started in line 10 and records the total time in took the network 
to run all of the simulations. 
For the simulations testing the different TVT ratios and training functions, only 
lines 16-20 were used to obtain the input and output data.  The input data for uncurated 
chemicals was not used in these simulations.  When adjusting the TVT ratios and training 
functions, lines 43-45 and 47 were the only lines of code that required editing. 
When the uncurated chemical data was used to generate disease value predictions, 
the code was first run using the original input and output to establish the network using 
the curate data.  Then the command “outputs=net(inputs1)” was entered into the 
MATLAB command window.  This told the network to use the new inputs containing the 
uncurated to derive disease value predicts.
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Appendix B: Input and Output Matrices 
Chemical Molecular Weight 
Hydrogen 
Acceptors 
Hydrogen 
Donors 
Species 
Number 
Dummy Variable 
Column 
Disease 
Number 
Acetone 
58.08 1 1 1 0 9 
58.08 1 1 1 0 12 
58.08 1 1 1 0 15 
58.08 1 1 1 0 16 
58.08 1 1 1 0 17 
58.08 1 1 1 0 25 
Aciclovir 
225.21 8 4 1 0 2 
225.21 8 4 1 0 3 
225.21 8 4 1 0 4 
225.21 8 4 1 0 5 
225.21 8 4 1 0 8 
225.21 8 4 1 0 9 
225.21 8 4 1 0 11 
225.21 8 4 1 0 12 
225.21 8 4 1 0 13 
225.21 8 4 1 0 15 
225.21 8 4 1 0 16 
225.21 8 4 1 0 17 
225.21 8 4 1 0 19 
225.21 8 4 1 0 20 
225.21 8 4 1 0 21 
225.21 8 4 1 0 23 
225.21 8 4 1 0 24 
225.21 8 4 1 0 25 
225.21 8 4 1 0 26 
Alprazolam 
308.77 4 0 1 0 3 
308.77 4 0 1 0 4 
308.77 4 0 1 0 5 
308.77 4 0 1 0 7 
308.77 4 0 1 0 8 
308.77 4 0 1 0 9 
308.77 4 0 1 0 11 
308.77 4 0 1 0 12 
308.77 4 0 1 0 13 
308.77 4 0 1 0 16 
308.77 4 0 1 0 21 
308.77 4 0 1 0 23 
308.77 4 0 1 0 25 
Ammonium Sulfate 
132.14 4 2 1 0 3 
132.14 4 2 1 0 17 
132.14 4 2 1 0 22 
Aspirin 180.16 4 1 1 0 2 
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180.16 4 1 1 0 3 
180.16 4 1 1 0 4 
180.16 4 1 1 0 5 
180.16 4 1 1 0 6 
180.16 4 1 1 0 7 
180.16 4 1 1 0 8 
180.16 4 1 1 0 9 
180.16 4 1 1 0 10 
180.16 4 1 1 0 11 
180.16 4 1 1 0 12 
180.16 4 1 1 0 13 
180.16 4 1 1 0 14 
180.16 4 1 1 0 15 
180.16 4 1 1 0 16 
180.16 4 1 1 0 17 
180.16 4 1 1 0 19 
180.16 4 1 1 0 21 
180.16 4 1 1 0 22 
180.16 4 1 1 0 23 
180.16 4 1 1 0 24 
180.16 4 1 1 0 25 
180.16 4 1 1 0 26 
180.16 4 1 1 0 27 
Atenolol 
266.34 5 4 1 0 3 
266.34 5 4 1 0 4 
266.34 5 4 1 0 5 
266.34 5 4 1 0 7 
266.34 5 4 1 0 9 
266.34 5 4 1 0 11 
266.34 5 4 1 0 12 
266.34 5 4 1 0 13 
266.34 5 4 1 0 14 
266.34 5 4 1 0 15 
266.34 5 4 1 0 16 
266.34 5 4 1 0 17 
266.34 5 4 1 0 21 
266.34 5 4 1 0 23 
266.34 5 4 1 0 24 
266.34 5 4 1 0 25 
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Azithromycin 
749.00 14 5 1 0 2 
749.00 14 5 1 0 3 
749.00 14 5 1 0 5 
749.00 14 5 1 0 7 
749.00 14 5 1 0 8 
749.00 14 5 1 0 9 
749.00 14 5 1 0 10 
749.00 14 5 1 0 11 
749.00 14 5 1 0 12 
749.00 14 5 1 0 13 
749.00 14 5 1 0 14 
749.00 14 5 1 0 15 
749.00 14 5 1 0 16 
749.00 14 5 1 0 17 
749.00 14 5 1 0 19 
749.00 14 5 1 0 21 
749.00 14 5 1 0 22 
749.00 14 5 1 0 23 
749.00 14 5 1 0 24 
749.00 14 5 1 0 24 
749.00 14 5 1 0 26 
Benzene 
78.12 0 0 5 0 1 
78.12 0 0 1 0 3 
78.12 0 0 1 0 4 
78.12 0 0 1 0 5 
78.12 0 0 1 0 7 
78.12 0 0 1 0 9 
78.12 0 0 1 0 10 
78.12 0 0 1 0 11 
78.12 0 0 1 0 14 
78.12 0 0 1 0 15 
78.12 0 0 1 0 16 
78.12 0 0 1 0 17 
78.12 0 0 1 0 18 
78.12 0 0 1 0 21 
78.12 0 0 1 0 22 
78.12 0 0 1 0 23 
78.12 0 0 1 0 25 
78.12 0 0 1 0 27 
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Benzyl-penicillin 
334.40 6 2 9 0 1 
334.40 6 2 1 0 2 
334.40 6 2 1 0 3 
334.40 6 2 1 0 4 
334.40 6 2 1 0 5 
334.40 6 2 1 0 7 
334.40 6 2 1 0 8 
334.40 6 2 1 0 9 
334.40 6 2 1 0 10 
334.40 6 2 1 0 11 
334.40 6 2 1 0 12 
334.40 6 2 1 0 14 
334.40 6 2 1 0 16 
334.40 6 2 1 0 17 
334.40 6 2 1 0 19 
334.40 6 2 1 0 20 
334.40 6 2 1 0 21 
334.40 6 2 1 0 22 
334.40 6 2 1 0 23 
334.40 6 2 1 0 24 
334.40 6 2 1 0 25 
334.40 6 2 1 0 26 
Caffeine 
194.19 6 0 9 0 1 
194.19 6 0 1 0 2 
194.19 6 0 1 0 3 
194.19 6 0 1 0 4 
194.19 6 0 1 0 5 
194.19 6 0 1 0 7 
194.19 6 0 1 0 8 
194.19 6 0 1 0 9 
194.19 6 0 1 0 10 
194.19 6 0 1 0 11 
194.19 6 0 1 0 12 
194.19 6 0 1 0 13 
194.19 6 0 1 0 14 
194.19 6 0 1 0 15 
194.19 6 0 1 0 16 
194.19 6 0 1 0 17 
194.19 6 0 1 0 19 
194.19 6 0 1 0 21 
194.19 6 0 1 0 22 
194.19 6 0 1 0 23 
194.19 6 0 1 0 25 
194.19 6 0 1 0 27 
Candoxatril 
515.65 8 2 1 0 3 
515.65 8 2 1 0 7 
515.65 8 2 1 0 16 
515.65 8 2 1 0 17 
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Carbamazepine 
236.28 3 2 9 0 1 
236.28 3 2 1 0 3 
236.28 3 2 1 0 4 
236.28 3 2 1 0 5 
236.28 3 2 1 0 7 
236.28 3 2 1 0 8 
236.28 3 2 1 0 9 
236.28 3 2 1 0 10 
236.28 3 2 1 0 11 
236.28 3 2 1 0 12 
236.28 3 2 1 0 13 
236.28 3 2 1 0 14 
236.28 3 2 1 0 15 
236.28 3 2 1 0 16 
236.28 3 2 1 0 17 
236.28 3 2 1 0 19 
236.28 3 2 1 0 21 
236.28 3 2 1 0 22 
236.28 3 2 1 0 23 
236.28 3 2 1 0 24 
236.28 3 2 1 0 25 
236.28 3 2 1 0 26 
Caustic Soda 
40.00 1 1 9 0 1 
40.00 1 1 1 0 5 
40.00 1 1 1 0 19 
40.00 1 1 1 0 22 
40.00 1 1 1 0 27 
Chloramphenicol 
323.14 7 3 1 0 2 
323.14 7 3 1 0 3 
323.14 7 3 1 0 5 
323.14 7 3 1 0 8 
323.14 7 3 1 0 9 
323.14 7 3 1 0 10 
323.14 7 3 1 0 11 
323.14 7 3 1 0 12 
323.14 7 3 1 0 14 
323.14 7 3 1 0 15 
323.14 7 3 1 0 16 
323.14 7 3 1 0 17 
323.14 7 3 1 0 19 
323.14 7 3 1 0 21 
323.14 7 3 1 0 22 
323.14 7 3 1 0 23 
323.14 7 3 1 0 25 
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Cimetidine 
252.34 6 3 1 0 2 
252.34 6 3 1 0 3 
252.34 6 3 1 0 4 
252.34 6 3 1 0 5 
252.34 6 3 1 0 7 
252.34 6 3 1 0 8 
252.34 6 3 1 0 9 
252.34 6 3 1 0 11 
252.34 6 3 1 0 12 
252.34 6 3 1 0 13 
252.34 6 3 1 0 14 
252.34 6 3 1 0 15 
252.34 6 3 1 0 16 
252.34 6 3 1 0 17 
252.34 6 3 1 0 19 
252.34 6 3 1 0 21 
252.34 6 3 1 0 22 
252.34 6 3 1 0 23 
252.34 6 3 1 0 24 
252.34 6 3 1 0 25 
252.34 6 3 1 0 26 
252.34 6 3 1 0 27 
Clonidine 
230.10 3 2 1 0 3 
230.10 3 2 1 0 4 
230.10 3 2 1 0 5 
230.10 3 2 1 0 7 
230.10 3 2 1 0 8 
230.10 3 2 1 0 9 
230.10 3 2 1 0 11 
230.10 3 2 1 0 12 
230.10 3 2 1 0 13 
230.10 3 2 1 0 14 
230.10 3 2 1 0 16 
230.10 3 2 1 0 17 
230.10 3 2 1 0 19 
230.10 3 2 1 0 21 
230.10 3 2 1 0 22 
230.10 3 2 1 0 23 
230.10 3 2 1 0 24 
230.10 3 2 1 0 25 
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Copper Sulfate 
159.61 4 0 1 0 4 
159.61 4 0 1 0 5 
159.61 4 0 1 0 9 
159.61 4 0 1 0 12 
159.61 4 0 1 0 13 
159.61 4 0 1 0 14 
159.61 4 0 1 0 16 
159.61 4 0 1 0 17 
159.61 4 0 1 0 19 
159.61 4 0 1 0 21 
159.61 4 0 1 0 22 
159.61 4 0 1 0 25 
Cyclosporine 
1202.64 23 5 9 0 1 
1202.64 23 5 1 0 2 
1202.64 23 5 1 0 3 
1202.64 23 5 1 0 4 
1202.64 23 5 1 0 5 
1202.64 23 5 1 0 7 
1202.64 23 5 1 0 8 
1202.64 23 5 1 0 9 
1202.64 23 5 1 0 10 
1202.64 23 5 1 0 11 
1202.64 23 5 1 0 12 
1202.64 23 5 1 0 13 
1202.64 23 5 1 0 14 
1202.64 23 5 1 0 15 
1202.64 23 5 1 0 16 
1202.64 23 5 1 0 17 
1202.64 23 5 1 0 19 
1202.64 23 5 1 0 20 
1202.64 23 5 1 0 21 
1202.64 23 5 1 0 22 
1202.64 23 5 1 0 23 
1202.64 23 5 1 0 23 
1202.64 23 5 1 0 25 
1202.64 23 5 1 0 26 
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Desipramine 
266.39 2 1 1 0 2 
266.39 2 1 1 0 3 
266.39 2 1 1 0 4 
266.39 2 1 1 0 5 
266.39 2 1 1 0 7 
266.39 2 1 1 0 8 
266.39 2 1 1 0 9 
266.39 2 1 1 0 11 
266.39 2 1 1 0 12 
266.39 2 1 1 0 13 
266.39 2 1 1 0 15 
266.39 2 1 1 0 16 
266.39 2 1 1 0 17 
266.39 2 1 1 0 21 
266.39 2 1 1 0 22 
266.39 2 1 1 0 23 
266.39 2 1 1 0 25 
Dexamethasone 
392.47 5 3 1 0 2 
392.47 5 3 1 0 3 
392.47 5 3 1 0 4 
392.47 5 3 1 0 5 
392.47 5 3 1 0 7 
392.47 5 3 1 0 8 
392.47 5 3 1 0 9 
392.47 5 3 1 0 10 
392.47 5 3 1 0 11 
392.47 5 3 1 0 12 
392.47 5 3 1 0 13 
392.47 5 3 1 0 14 
392.47 5 3 1 0 15 
392.47 5 3 1 0 16 
392.47 5 3 1 0 17 
392.47 5 3 1 0 19 
392.47 5 3 1 0 20 
392.47 5 3 1 0 21 
392.47 5 3 1 0 22 
392.47 5 3 1 0 23 
392.47 5 3 1 0 24 
392.47 5 3 1 0 25 
392.47 5 3 1 0 26 
392.47 5 3 1 0 27 
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Diazepam 
284.75 3 0 1 0 2 
284.75 3 0 1 0 2 
284.75 3 0 1 0 4 
284.75 3 0 1 0 5 
284.75 3 0 1 0 8 
284.75 3 0 1 0 9 
284.75 3 0 1 0 11 
284.75 3 0 1 0 12 
284.75 3 0 1 0 13 
284.75 3 0 1 0 14 
284.75 3 0 1 0 15 
284.75 3 0 1 0 16 
284.75 3 0 1 0 17 
284.75 3 0 1 0 19 
284.75 3 0 1 0 21 
284.75 3 0 1 0 22 
284.75 3 0 1 0 23 
284.75 3 0 1 0 24 
284.75 3 0 1 0 25 
284.75 3 0 1 0 27 
Diclofenac 
296.15 3 2 1 0 2 
296.15 3 2 1 0 3 
296.15 3 2 1 0 4 
296.15 3 2 1 0 5 
296.15 3 2 1 0 7 
296.15 3 2 1 0 8 
296.15 3 2 1 0 9 
296.15 3 2 1 0 11 
296.15 3 2 1 0 12 
296.15 3 2 1 0 13 
296.15 3 2 1 0 14 
296.15 3 2 1 0 15 
296.15 3 2 1 0 16 
296.15 3 2 1 0 17 
296.15 3 2 1 0 19 
296.15 3 2 1 0 21 
296.15 3 2 1 0 22 
296.15 3 2 1 0 23 
296.15 3 2 1 0 25 
296.15 3 2 1 0 26 
296.15 3 2 1 0 27 
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Diltiazem-HCl 
414.53 6 0 1 0 3 
414.53 6 0 1 0 4 
414.53 6 0 1 0 4 
414.53 6 0 1 0 7 
414.53 6 0 1 0 8 
414.53 6 0 1 0 9 
414.53 6 0 1 0 10 
414.53 6 0 1 0 11 
414.53 6 0 1 0 12 
414.53 6 0 1 0 13 
414.53 6 0 1 0 14 
414.53 6 0 1 0 15 
414.53 6 0 1 0 16 
414.53 6 0 1 0 17 
414.53 6 0 1 0 21 
414.53 6 0 1 0 23 
414.53 6 0 1 0 25 
Doxorubicin 
543.53 12 7 9 0 1 
543.53 12 7 1 0 2 
543.53 12 7 1 0 3 
543.53 12 7 1 0 4 
543.53 12 7 1 0 5 
543.53 12 7 1 0 7 
543.53 12 7 1 0 8 
543.53 12 7 1 0 9 
543.53 12 7 1 0 10 
543.53 12 7 1 0 11 
543.53 12 7 1 0 12 
543.53 12 7 1 0 13 
543.53 12 7 1 0 14 
543.53 12 7 1 0 15 
543.53 12 7 1 0 16 
543.53 12 7 1 0 17 
543.53 12 7 1 0 19 
543.53 12 7 1 0 21 
543.53 12 7 1 0 22 
543.53 12 7 1 0 23 
543.53 12 7 1 0 24 
543.53 12 7 1 0 25 
543.53 12 7 1 0 26 
543.53 12 7 1 0 27 
Enalaprilat 
376.46 7 2 1 0 3 
376.46 7 2 1 0 5 
376.46 7 2 1 0 21 
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Erythromycin 
733.95 14 5 9 0 1 
733.95 14 5 1 0 2 
733.95 14 5 1 0 3 
733.95 14 5 1 0 4 
733.95 14 5 1 0 5 
733.95 14 5 1 0 7 
733.95 14 5 1 0 8 
733.95 14 5 1 0 9 
733.95 14 5 1 0 10 
733.95 14 5 1 0 11 
733.95 14 5 1 0 12 
733.95 14 5 1 0 13 
733.95 14 5 1 0 14 
733.95 14 5 1 0 15 
733.95 14 5 1 0 16 
733.95 14 5 1 0 17 
733.95 14 5 1 0 19 
733.95 14 5 1 0 20 
733.95 14 5 1 0 21 
733.95 14 5 1 0 22 
733.95 14 5 1 0 23 
733.95 14 5 1 0 24 
733.95 14 5 1 0 25 
733.95 14 5 1 0 26 
Ethylene Glycol 
62.07 2 2 1 0 4 
62.07 2 2 1 0 5 
62.07 2 2 1 0 9 
62.07 2 2 1 0 12 
62.07 2 2 1 0 14 
62.07 2 2 1 0 16 
62.07 2 2 1 0 25 
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Famotidine 
337.45 9 8 1 0 3 
337.45 9 8 1 0 4 
337.45 9 8 1 0 5 
337.45 9 8 1 0 7 
337.45 9 8 1 0 9 
337.45 9 8 1 0 11 
337.45 9 8 1 0 12 
337.45 9 8 1 0 13 
337.45 9 8 1 0 14 
337.45 9 8 1 0 15 
337.45 9 8 1 0 16 
337.45 9 8 1 0 17 
337.45 9 8 1 0 21 
337.45 9 8 1 0 22 
337.45 9 8 1 0 23 
337.45 9 8 1 0 25 
337.45 9 8 1 0 26 
337.45 9 8 1 0 27 
Felodipine 
384.26 5 1 1 0 3 
384.26 5 1 1 0 9 
384.26 5 1 1 0 12 
384.26 5 1 1 0 16 
384.26 5 1 1 0 21 
384.26 5 1 1 0 23 
384.26 5 1 1 0 24 
Ferric Chloride 
162.20 0 0 1 0 3 
162.20 0 0 1 0 5 
162.20 0 0 1 0 9 
162.20 0 0 1 0 11 
162.20 0 0 1 0 12 
162.20 0 0 1 0 16 
162.20 0 0 1 0 21 
162.20 0 0 1 0 25 
162.20 0 0 1 0 27 
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Fluorouracil 
130.08 4 2 1 0 2 
130.08 4 2 1 0 3 
130.08 4 2 1 0 4 
130.08 4 2 1 0 5 
130.08 4 2 1 0 7 
130.08 4 2 1 0 8 
130.08 4 2 1 0 9 
130.08 4 2 1 0 10 
130.08 4 2 1 0 11 
130.08 4 2 1 0 12 
130.08 4 2 1 0 13 
130.08 4 2 1 0 14 
130.08 4 2 1 0 15 
130.08 4 2 1 0 16 
130.08 4 2 1 0 17 
130.08 4 2 1 0 19 
130.08 4 2 1 0 21 
130.08 4 2 1 0 22 
130.08 4 2 1 0 23 
130.08 4 2 1 0 24 
130.08 4 2 1 0 25 
130.08 4 2 1 0 26 
130.08 4 2 1 0 27 
Flurbiprofen 
244.27 2 1 1 0 3 
244.27 2 1 1 0 4 
244.27 2 1 1 0 5 
244.27 2 1 1 0 8 
244.27 2 1 1 0 9 
244.27 2 1 1 0 11 
244.27 2 1 1 0 12 
244.27 2 1 1 0 13 
244.27 2 1 1 0 14 
244.27 2 1 1 0 15 
244.27 2 1 1 0 16 
244.27 2 1 1 0 17 
244.27 2 1 1 0 19 
244.27 2 1 1 0 21 
244.27 2 1 1 0 22 
244.27 2 1 1 0 23 
244.27 2 1 1 0 24 
244.27 2 1 1 0 25 
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Formaldehyde 
30.03 1 0 3 0 1 
30.03 1 0 5 0 1 
30.03 1 0 1 0 2 
30.03 1 0 1 0 3 
30.03 1 0 1 0 4 
30.03 1 0 1 0 5 
30.03 1 0 1 0 7 
30.03 1 0 1 0 8 
30.03 1 0 1 0 9 
30.03 1 0 1 0 11 
30.03 1 0 1 0 12 
30.03 1 0 1 0 13 
30.03 1 0 1 0 14 
30.03 1 0 1 0 15 
30.03 1 0 1 0 16 
30.03 1 0 1 0 18 
30.03 1 0 1 0 19 
30.03 1 0 1 0 20 
30.03 1 0 1 0 21 
30.03 1 0 1 0 22 
30.03 1 0 1 0 23 
30.03 1 0 1 0 24 
30.03 1 0 1 0 25 
30.03 1 0 1 0 26 
Furosemide 
330.75 7 4 1 0 3 
330.75 7 4 1 0 4 
330.75 7 4 1 0 5 
330.75 7 4 1 0 7 
330.75 7 4 1 0 9 
330.75 7 4 1 0 10 
330.75 7 4 1 0 11 
330.75 7 4 1 0 12 
330.75 7 4 1 0 13 
330.75 7 4 1 0 14 
330.75 7 4 1 0 15 
330.75 7 4 1 0 16 
330.75 7 4 1 0 17 
330.75 7 4 1 0 19 
330.75 7 4 1 0 21 
330.75 7 4 1 0 22 
330.75 7 4 1 0 23 
330.75 7 4 1 0 25 
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Gabapentin 
30.03 1 0 1 0 27 
171.24 3 2 1 0 3 
171.24 3 2 1 0 4 
171.24 3 2 1 0 5 
171.24 3 2 1 0 7 
171.24 3 2 1 0 8 
171.24 3 2 1 0 9 
171.24 3 2 1 0 12 
171.24 3 2 1 0 13 
171.24 3 2 1 0 15 
171.24 3 2 1 0 16 
171.24 3 2 1 0 17 
171.24 3 2 1 0 21 
171.24 3 2 1 0 23 
171.24 3 2 1 0 24 
Glycerol 
92.09 3 3 9 0 1 
92.09 3 3 1 0 3 
92.09 3 3 1 0 7 
92.09 3 3 1 0 8 
92.09 3 3 1 0 9 
92.09 3 3 1 0 12 
92.09 3 3 1 0 14 
92.09 3 3 1 0 16 
92.09 3 3 1 0 17 
92.09 3 3 1 0 21 
Hydrobromic Acid 171.24 3 2 1 0 25 
80.91 0 0 1 0 16 
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Hydrochloric Acid 
36.46 0 1 1 0 2 
36.46 0 1 1 0 3 
36.46 0 1 1 0 4 
36.46 0 1 1 0 5 
36.46 0 1 1 0 7 
36.46 0 1 1 0 9 
36.46 0 1 1 0 11 
36.46 0 1 1 0 12 
36.46 0 1 1 0 13 
36.46 0 1 1 0 14 
36.46 0 1 1 0 15 
36.46 0 1 1 0 16 
36.46 0 1 1 0 17 
36.46 0 1 1 0 18 
36.46 0 1 1 0 19 
36.46 0 1 1 0 20 
36.46 0 1 1 0 21 
36.46 0 1 1 0 22 
36.46 0 1 1 0 23 
36.46 0 1 1 0 24 
36.46 0 1 1 0 25 
36.46 0 1 1 0 27 
Hydrochlorothiazide 
297.74 7 4 1 0 3 
297.74 7 4 1 0 4 
297.74 7 4 1 0 5 
297.74 7 4 1 0 7 
297.74 7 4 1 0 9 
297.74 7 4 1 0 11 
297.74 7 4 1 0 12 
297.74 7 4 1 0 13 
297.74 7 4 1 0 14 
297.74 7 4 1 0 16 
297.74 7 4 1 0 17 
297.74 7 4 1 0 21 
297.74 7 4 1 0 22 
297.74 7 4 1 0 23 
297.74 7 4 1 0 24 
297.74 7 4 1 0 25 
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Hydrofluoric Acid 
20.01 1 1 1 0 5 
20.01 1 1 1 0 9 
20.01 1 1 1 0 12 
20.01 1 1 1 0 13 
20.01 1 1 1 0 14 
20.01 1 1 1 0 16 
20.01 1 1 1 0 17 
20.01 1 1 1 0 21 
20.01 1 1 1 0 22 
20.01 1 1 1 0 24 
20.01 1 1 1 0 25 
20.01 1 1 1 0 27 
Ibuprofen 
206.29 2 1 1 0 2 
206.29 2 1 1 0 3 
206.29 2 1 1 0 4 
206.29 2 1 1 0 5 
206.29 2 1 1 0 7 
206.29 2 1 1 0 8 
206.29 2 1 1 0 9 
206.29 2 1 1 0 10 
206.29 2 1 1 0 11 
206.29 2 1 1 0 12 
206.29 2 1 1 0 13 
206.29 2 1 1 0 14 
206.29 2 1 1 0 15 
206.29 2 1 1 0 16 
206.29 2 1 1 0 17 
206.29 2 1 1 0 19 
206.29 2 1 1 0 21 
206.29 2 1 1 0 22 
206.29 2 1 1 0 23 
206.29 2 1 1 0 24 
206.29 2 1 1 0 25 
206.29 2 1 1 0 26 
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Imipramine 
280.42 2 0 1 0 3 
280.42 2 0 1 0 4 
280.42 2 0 1 0 5 
280.42 2 0 1 0 7 
280.42 2 0 1 0 8 
280.42 2 0 1 0 9 
280.42 2 0 1 0 11 
280.42 2 0 1 0 12 
280.42 2 0 1 0 13 
280.42 2 0 1 0 14 
280.42 2 0 1 0 15 
280.42 2 0 1 0 16 
280.42 2 0 1 0 17 
280.42 2 0 1 0 19 
280.42 2 0 1 0 21 
280.42 2 0 1 0 22 
280.42 2 0 1 0 23 
280.42 2 0 1 0 24 
280.42 2 0 1 0 25 
Isopropyl Alcohol 60.10 1 1 1 0 2 
Itraconazole 
705.65 12 0 1 0 2 
705.65 12 0 1 0 3 
705.65 12 0 1 0 4 
705.65 12 0 1 0 5 
705.65 12 0 1 0 7 
705.65 12 0 1 0 9 
705.65 12 0 1 0 11 
705.65 12 0 1 0 12 
705.65 12 0 1 0 13 
705.65 12 0 1 0 14 
705.65 12 0 1 0 15 
705.65 12 0 1 0 16 
705.65 12 0 1 0 17 
705.65 12 0 1 0 19 
705.65 12 0 1 0 20 
705.65 12 0 1 0 21 
705.65 12 0 1 0 22 
705.65 12 0 1 0 23 
705.65 12 0 1 0 25 
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Ketoconazole 
380.92 1 0 9 0 1 
380.92 1 0 1 0 2 
380.92 1 0 1 0 3 
380.92 1 0 1 0 4 
380.92 1 0 1 0 5 
380.92 1 0 1 0 7 
380.92 1 0 1 0 8 
380.92 1 0 1 0 9 
380.92 1 0 1 0 11 
380.92 1 0 1 0 12 
380.92 1 0 1 0 13 
380.92 1 0 1 0 14 
380.92 1 0 1 0 15 
380.92 1 0 1 0 16 
380.92 1 0 1 0 17 
380.92 1 0 1 0 20 
380.92 1 0 1 0 21 
380.92 1 0 1 0 22 
380.92 1 0 1 0 23 
380.92 1 0 1 0 24 
380.92 1 0 1 0 25 
380.92 1 0 1 0 27 
Ketoprofen 
254.29 3 1 1 0 3 
254.29 3 1 1 0 4 
254.29 3 1 1 0 5 
254.29 3 1 1 0 9 
254.29 3 1 1 0 11 
254.29 3 1 1 0 12 
254.29 3 1 1 0 13 
254.29 3 1 1 0 14 
254.29 3 1 1 0 16 
254.29 3 1 1 0 21 
254.29 3 1 1 0 22 
254.29 3 1 1 0 23 
254.29 3 1 1 0 25 
254.29 3 1 1 0 27 
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Labetalol-HCl 
328.42 5 5 1 0 2 
328.42 5 5 1 0 3 
328.42 5 5 1 0 4 
328.42 5 5 1 0 4 
328.42 5 5 1 0 5 
328.42 5 5 1 0 7 
328.42 5 5 1 0 9 
328.42 5 5 1 0 11 
328.42 5 5 1 0 12 
328.42 5 5 1 0 13 
328.42 5 5 1 0 14 
328.42 5 5 1 0 15 
328.42 5 5 1 0 16 
328.42 5 5 1 0 17 
328.42 5 5 1 0 21 
328.42 5 5 1 0 22 
328.42 5 5 1 0 23 
328.42 5 5 1 0 25 
Lisinopril 
405.50 8 5 1 0 3 
405.50 8 5 1 0 4 
405.50 8 5 1 0 5 
405.50 8 5 1 0 7 
405.50 8 5 1 0 8 
405.50 8 5 1 0 9 
405.50 8 5 1 0 11 
405.50 8 5 1 0 12 
405.50 8 5 1 0 13 
405.50 8 5 1 0 14 
405.50 8 5 1 0 16 
405.50 8 5 1 0 17 
405.50 8 5 1 0 21 
405.50 8 5 1 0 22 
405.50 8 5 1 0 23 
405.50 8 5 1 0 24 
405.50 8 5 1 0 25 
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Magnesium Sulfate 
120.37 4 0 1 0 2 
120.37 4 0 1 0 3 
120.37 4 0 1 0 4 
120.37 4 0 1 0 5 
120.37 4 0 1 0 8 
120.37 4 0 1 0 9 
120.37 4 0 1 0 11 
120.37 4 0 1 0 12 
120.37 4 0 1 0 13 
120.37 4 0 1 0 14 
120.37 4 0 1 0 16 
120.37 4 0 1 0 17 
120.37 4 0 1 0 21 
120.37 4 0 1 0 22 
120.37 4 0 1 0 25 
120.37 4 0 1 0 27 
Mannitol 
182.18 6 6 1 0 3 
182.18 6 6 1 0 5 
182.18 6 6 1 0 7 
182.18 6 6 1 0 8 
182.18 6 6 1 0 9 
182.18 6 6 1 0 11 
182.18 6 6 1 0 12 
182.18 6 6 1 0 14 
182.18 6 6 1 0 15 
182.18 6 6 1 0 16 
182.18 6 6 1 0 17 
182.18 6 6 1 0 21 
182.18 6 6 1 0 22 
182.18 6 6 1 0 23 
182.18 6 6 1 0 24 
182.18 6 6 1 0 25 
182.18 6 6 1 0 26 
182.18 6 6 1 0 27 
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Methotrexate 
454.45 13 7 1 0 2 
454.45 13 7 1 0 3 
454.45 13 7 1 0 4 
454.45 13 7 1 0 4 
454.45 13 7 1 0 5 
454.45 13 7 1 0 7 
454.45 13 7 1 0 8 
454.45 13 7 1 0 9 
454.45 13 7 1 0 10 
454.45 13 7 1 0 11 
454.45 13 7 1 0 12 
454.45 13 7 1 0 13 
454.45 13 7 1 0 14 
454.45 13 7 1 0 15 
454.45 13 7 1 0 16 
454.45 13 7 1 0 17 
454.45 13 7 1 0 19 
454.45 13 7 1 0 21 
454.45 13 7 1 0 22 
454.45 13 7 1 0 23 
454.45 13 7 1 0 24 
454.45 13 7 1 0 25 
454.45 13 7 1 0 26 
454.45 13 7 1 0 27 
Metoprolol-tartrate 
267.37 4 2 1 0 3 
267.37 4 2 1 0 4 
267.37 4 2 1 0 5 
267.37 4 2 1 0 7 
267.37 4 2 1 0 8 
267.37 4 2 1 0 9 
267.37 4 2 1 0 11 
267.37 4 2 1 0 12 
267.37 4 2 1 0 13 
267.37 4 2 1 0 14 
267.37 4 2 1 0 15 
267.37 4 2 1 0 16 
267.37 4 2 1 0 17 
267.37 4 2 1 0 21 
267.37 4 2 1 0 22 
267.37 4 2 1 0 23 
267.37 4 2 1 0 24 
267.37 4 2 1 0 25 
267.37 4 2 1 0 27 
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Nadolol 
309.41 5 4 1 0 3 
309.41 5 4 1 0 5 
309.41 5 4 1 0 7 
309.41 5 4 1 0 11 
309.41 5 4 1 0 13 
309.41 5 4 1 0 16 
309.41 5 4 1 0 21 
309.41 5 4 1 0 23 
309.41 5 4 1 0 24 
309.41 5 4 1 0 25 
Naloxone 
327.38 5 2 1 0 2 
327.38 5 2 1 0 3 
327.38 5 2 1 0 4 
327.38 5 2 1 0 5 
327.38 5 2 1 0 7 
327.38 5 2 1 0 8 
327.38 5 2 1 0 9 
327.38 5 2 1 0 10 
327.38 5 2 1 0 11 
327.38 5 2 1 0 12 
327.38 5 2 1 0 13 
327.38 5 2 1 0 14 
327.38 5 2 1 0 15 
327.38 5 2 1 0 16 
327.38 5 2 1 0 17 
327.38 5 2 1 0 19 
327.38 5 2 1 0 21 
327.38 5 2 1 0 22 
327.38 5 2 1 0 23 
327.38 5 2 1 0 24 
327.38 5 2 1 0 25 
327.38 5 2 1 0 27 
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Naproxen-sodium 
230.27 3 1 1 0 2 
230.27 3 1 1 0 3 
230.27 3 1 1 0 4 
230.27 3 1 1 0 5 
230.27 3 1 1 0 7 
230.27 3 1 1 0 9 
230.27 3 1 1 0 11 
230.27 3 1 1 0 12 
230.27 3 1 1 0 13 
230.27 3 1 1 0 14 
230.27 3 1 1 0 16 
230.27 3 1 1 0 17 
230.27 3 1 1 0 19 
230.27 3 1 1 0 21 
230.27 3 1 1 0 22 
230.27 3 1 1 0 23 
230.27 3 1 1 0 24 
230.27 3 1 1 0 25 
230.27 3 1 1 0 26 
230.27 3 1 1 0 27 
Nortriptylene-HCl 
263.39 1 1 1 0 3 
263.39 1 1 1 0 4 
263.39 1 1 1 0 5 
263.39 1 1 1 0 8 
263.39 1 1 1 0 9 
263.39 1 1 1 0 12 
263.39 1 1 1 0 13 
263.39 1 1 1 0 16 
263.39 1 1 1 0 17 
263.39 1 1 1 0 19 
263.39 1 1 1 0 21 
263.39 1 1 1 0 22 
263.39 1 1 1 0 24 
263.39 1 1 1 0 25 
263.39 1 1 1 0 27 
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Omeprazole 
267.25 9 2 1 0 2 
267.25 9 2 1 0 3 
267.25 9 2 1 0 4 
267.25 9 2 1 0 5 
267.25 9 2 1 0 7 
267.25 9 2 1 0 8 
267.25 9 2 1 0 9 
267.25 9 2 1 0 11 
267.25 9 2 1 0 12 
267.25 9 2 1 0 13 
267.25 9 2 1 0 14 
267.25 9 2 1 0 15 
267.25 9 2 1 0 16 
267.25 9 2 1 0 17 
267.25 9 2 1 0 19 
267.25 9 2 1 0 20 
267.25 9 2 1 0 21 
267.25 9 2 1 0 22 
267.25 9 2 1 0 23 
267.25 9 2 1 0 24 
267.25 9 2 1 0 25 
Phenytoin 
451.49 10 2 1 0 3 
451.49 10 2 1 0 4 
451.49 10 2 1 0 5 
451.49 10 2 1 0 7 
451.49 10 2 1 0 8 
451.49 10 2 1 0 9 
451.49 10 2 1 0 10 
451.49 10 2 1 0 11 
451.49 10 2 1 0 12 
451.49 10 2 1 0 13 
451.49 10 2 1 0 14 
451.49 10 2 1 0 15 
451.49 10 2 1 0 16 
451.49 10 2 1 0 17 
451.49 10 2 1 0 19 
451.49 10 2 1 0 21 
451.49 10 2 1 0 22 
451.49 10 2 1 0 23 
451.49 10 2 1 0 24 
451.49 10 2 1 0 25 
451.49 10 2 1 0 26 
451.49 10 2 1 0 27 
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Piroxicam 
331.35 7 2 1 0 3 
331.35 7 2 1 0 4 
331.35 7 2 1 0 5 
331.35 7 2 1 0 8 
331.35 7 2 1 0 9 
331.35 7 2 1 0 11 
331.35 7 2 1 0 12 
331.35 7 2 1 0 14 
331.35 7 2 1 0 15 
331.35 7 2 1 0 16 
331.35 7 2 1 0 17 
331.35 7 2 1 0 19 
331.35 7 2 1 0 21 
331.35 7 2 1 0 22 
331.35 7 2 1 0 23 
331.35 7 2 1 0 25 
331.35 7 2 1 0 26 
331.35 7 2 1 0 27 
Potassium Bromide 119.00 1 0 1 0 16 
Potassium Permanganate 158.03 4 0 1 0 5 
Prazosin 
383.41 9 2 1 0 3 
383.41 9 2 1 0 4 
383.41 9 2 1 0 5 
383.41 9 2 1 0 7 
383.41 9 2 1 0 8 
383.41 9 2 1 0 9 
383.41 9 2 1 0 11 
383.41 9 2 1 0 12 
383.41 9 2 1 0 13 
383.41 9 2 1 0 14 
383.41 9 2 1 0 15 
383.41 9 2 1 0 16 
383.41 9 2 1 0 17 
383.41 9 2 1 0 21 
383.41 9 2 1 0 23 
383.41 9 2 1 0 25 
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Propranolol-HCl 
259.35 3 2 1 0 3 
259.35 3 2 1 0 4 
259.35 3 2 1 0 5 
259.35 3 2 1 0 7 
259.35 3 2 1 0 8 
259.35 3 2 1 0 9 
259.35 3 2 1 0 11 
259.35 3 2 1 0 12 
259.35 3 2 1 0 13 
259.35 3 2 1 0 14 
259.35 3 2 1 0 15 
259.35 3 2 1 0 16 
259.35 3 2 1 0 17 
259.35 3 2 1 0 19 
259.35 3 2 1 0 21 
259.35 3 2 1 0 22 
259.35 3 2 1 0 23 
259.35 3 2 1 0 24 
259.35 3 2 1 0 25 
259.35 3 2 1 0 27 
Quinidine 
324.43 4 1 1 0 3 
324.43 4 1 1 0 4 
324.43 4 1 1 0 5 
324.43 4 1 1 0 8 
324.43 4 1 1 0 9 
324.43 4 1 1 0 10 
324.43 4 1 1 0 11 
324.43 4 1 1 0 12 
324.43 4 1 1 0 13 
324.43 4 1 1 0 14 
324.43 4 1 1 0 16 
324.43 4 1 1 0 17 
324.43 4 1 1 0 19 
324.43 4 1 1 0 20 
324.43 4 1 1 0 21 
324.43 4 1 1 0 22 
324.43 4 1 1 0 23 
324.43 4 1 1 0 25 
 102 
Ranitidine-HCl 
314.41 7 2 1 0 2 
314.41 7 2 1 0 3 
314.41 7 2 1 0 3 
314.41 7 2 1 0 5 
314.41 7 2 1 0 7 
314.41 7 2 1 0 8 
314.41 7 2 1 0 9 
314.41 7 2 1 0 11 
314.41 7 2 1 0 12 
314.41 7 2 1 0 13 
314.41 7 2 1 0 14 
314.41 7 2 1 0 15 
314.41 7 2 1 0 16 
314.41 7 2 1 0 17 
314.41 7 2 1 0 19 
314.41 7 2 1 0 21 
314.41 7 2 1 0 22 
314.41 7 2 1 0 23 
314.41 7 2 1 0 24 
314.41 7 2 1 0 25 
314.41 7 2 1 0 26 
314.41 7 2 1 0 27 
Silver Nitrate 169.87 3 0 1 0 11 
Sodium Thiosulfate 
158.11 4 0 1 0 9 
158.11 4 0 1 0 12 
158.11 4 0 1 0 16 
158.11 4 0 1 0 17 
158.11 4 0 1 0 19 
158.11 4 0 1 0 25 
Tenidap 
320.76 5 2 1 0 9 
320.76 5 2 1 0 11 
320.76 5 2 1 0 12 
320.76 5 2 1 0 14 
320.76 5 2 1 0 23 
 103 
Terfenadine 
471.69 3 2 1 0 3 
471.69 3 2 1 0 4 
471.69 3 2 1 0 5 
471.69 3 2 1 0 9 
471.69 3 2 1 0 11 
471.69 3 2 1 0 12 
471.69 3 2 1 0 14 
471.69 3 2 1 0 15 
471.69 3 2 1 0 16 
471.69 3 2 1 0 17 
471.69 3 2 1 0 19 
471.69 3 2 1 0 21 
471.69 3 2 1 0 22 
471.69 3 2 1 0 23 
471.69 3 2 1 0 25 
Testosterone 
288.43 2 1 9 0 1 
288.43 2 1 1 0 3 
288.43 2 1 1 0 4 
288.43 2 1 1 0 5 
288.43 2 1 1 0 7 
288.43 2 1 1 0 9 
288.43 2 1 1 0 10 
288.43 2 1 1 0 11 
288.43 2 1 1 0 12 
288.43 2 1 1 0 13 
288.43 2 1 1 0 15 
288.43 2 1 1 0 16 
288.43 2 1 1 0 17 
288.43 2 1 1 0 19 
288.43 2 1 1 0 20 
288.43 2 1 1 0 21 
288.43 2 1 1 0 22 
288.43 2 1 1 0 23 
288.43 2 1 1 0 25 
288.43 2 1 1 0 26 
288.43 2 1 1 0 27 
Trovafloxacin 
416.36 7 3 1 0 2 
416.36 7 3 1 0 3 
416.36 7 3 1 0 5 
416.36 7 3 1 0 9 
416.36 7 3 1 0 12 
416.36 7 3 1 0 14 
416.36 7 3 1 0 16 
416.36 7 3 1 0 21 
416.36 7 3 1 0 25 
 104 
Valproic-acid 
144.22 2 1 9 0 1 
144.22 2 1 1 0 3 
144.22 2 1 1 0 4 
144.22 2 1 1 0 5 
144.22 2 1 1 0 7 
144.22 2 1 1 0 8 
144.22 2 1 1 0 9 
144.22 2 1 1 0 10 
144.22 2 1 1 0 11 
144.22 2 1 1 0 12 
144.22 2 1 1 0 13 
144.22 2 1 1 0 14 
144.22 2 1 1 0 15 
144.22 2 1 1 0 16 
144.22 2 1 1 0 17 
144.22 2 1 1 0 19 
144.22 2 1 1 0 21 
144.22 2 1 1 0 22 
144.22 2 1 1 0 23 
144.22 2 1 1 0 24 
144.22 2 1 1 0 25 
144.22 2 1 1 0 27 
Vinblastine 
811.00 13 3 1 0 2 
811.00 13 3 1 0 3 
811.00 13 3 1 0 4 
811.00 13 3 1 0 5 
811.00 13 3 1 0 7 
811.00 13 3 1 0 8 
811.00 13 3 1 0 9 
811.00 13 3 1 0 10 
811.00 13 3 1 0 11 
811.00 13 3 1 0 12 
811.00 13 3 1 0 13 
811.00 13 3 1 0 14 
811.00 13 3 1 0 15 
811.00 13 3 1 0 16 
811.00 13 3 1 0 17 
811.00 13 3 1 0 19 
811.00 13 3 1 0 21 
811.00 13 3 1 0 22 
811.00 13 3 1 0 23 
811.00 13 3 1 0 24 
811.00 13 3 1 0 25 
811.00 13 3 1 0 26 
 105 
Zinc Chloride 
136.29 0 0 1 0 5 
136.29 0 0 1 0 13 
136.29 0 0 1 0 15 
136.29 0 0 1 0 21 
136.29 0 0 1 0 25 
Ziprasidone 
412.95 5 1 1 0 3 
412.95 5 1 1 0 4 
412.95 5 1 1 0 5 
412.95 5 1 1 0 7 
412.95 5 1 1 0 11 
412.95 5 1 1 0 13 
412.95 5 1 1 0 14 
412.95 5 1 1 0 16 
412.95 5 1 1 0 19 
412.95 5 1 1 0 21 
412.95 5 1 1 0 22 
412.95 5 1 1 0 23 
412.95 5 1 1 0 25 
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Appendix C: Additional MATLAB Training Sessions 
Figures C.1-C.7 shows the ANN simulations results for a network using the 
training function trainscg.  The trainscg training function is similar the default function 
shown in Chapter 4, but it uses a scaled conjugate gradient to train the data in the 
network.  Trainscg also does not use mu as a network parameter to measure how well the 
network is performing during training.  This session was terminated due to the upper 
limits of epochs being reached.  Even through the network reached the maximum number 
of epochs, it still performed fairly well with an R-value of 0.93898.  Figure C.2 shows 
that the actual versus ANN derived disease plot appeared to follow a linear line but did 
have some curve to it.  This curve to the output data would explain the R-value being less 
than one.  The performance and MSE plots (figures C.3 and C.4) look identical because 
MSE is used with trainscg to measure the network performance.  It should also be noted 
that the network was consistently able to lower the performance/MSE over the course of 
the simulation indicating the network was able to continually improve over time.  Figure 
C.5 shows the regression plot which makes it clear that the ANN derived disease values 
did not directly lay along the one-to-one slope.  Figure C.6 shows numerous fluctuations 
in the gradient and the network tried to increase the performance and Figure C.7 shows 
the error histogram highlighting that most of the error in the network was small, but not 
small enough to produce a linear output.  
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Figure C.1: Trainscg Training Session 
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Figure C.2: Trainscg Actual Disease versus ANN Derived Disease Outputs Plot 
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Figure C.3: Trainscg Performance Plot 
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Figure C.4: Trainscg Mean Squared Error Plot  
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Figure C.5: Trainscg Regression Plot 
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Figure C.6: Transcg Training States 
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Figure C.7: Trainscg Error Histogram  
. 
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Figures C.8-C.14 shows the ANN simulations results for a network using the 
training function trainrp.  The trainrp training function is similar the default function 
shown in Chapter 4, but it uses resilient backpropagation to train the data in the network.  
Trainrp also does not use mu as a network parameter to measure how well the network is 
performing during training.  This session was terminated due to the gradient lower limit 
indicating the network potentially performed well.  However, then reviewing Figure C.9 
and the R-value, it is apparent the ANN derived disease values do not follow a one-to-one 
slope.  In addition to the R-value of 0.53903, the regressions plot in figure C.12 shows 
the ANN derived disease values follow a slope of 0.5 to 1 which indicates the network 
predict values half that of the actual values.  The performance and MSE plots (Figures 
C.9 and C.10) look identical because MSE is used with trainscg to measure the network 
performance.  Figure C.13 shows a consistently decreasing gradient and Figure C.14 
shows the error histogram highlighting that minimal error occurred over a wide range, the 
majority of the error was small. 
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Figure C.8: Trainrp Training Session 
 116 
 
Figure C.9: Trainsrp Actual Disease versus ANN Derived Disease Outputs Plot 
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Figure C.10: Trainrp Performance Plot 
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Figure C.11: Trainrp Mean Squared Error Plot 
 119 
 
Figure C.12: Trainrp Regression Plot 
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Figure C.13: Trainrp Training Parameters 
 121 
 
Figure C.14: Trainrp Error Histogram 
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Appendix D: TVT Graphs 
The following figures show the results of the five ANN simulations for each TVT 
ratio.  The 70-15-15 percent and 80-10-10 percent ratios were the only ones to produce 
linear plots where all of the ANN derived values were positive and the 70-15-15 percent 
ratio was the only one to produce ANN derived values on the one-to-one slope for all five 
simulations.  The default train training function was used for all of the TVT simulations. 
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Figure D.1: 50-25-25 % TVT Ratio Plot 
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Figure D.2: 60-20-20% TVT Ratio Plot 
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Figure D.3: 70-15-15% TVT Ratio Plot 
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Figure D.4: 80-10-10% TVT Ratio Plot 
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Figure D.5: 90-5-5% TVT Ratio Plot 
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Appendix E: List of Training Functions 
Table E.1 shows each of the training functions used in the ANN simulations along 
with a brief of description of how each function trains the network.  All of the 
descriptions were found in the MATLAB Neural Network Toolbox Reference Guide.  
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Table E.1: Training Function Descriptions 
 
Training 
Function Description 
train Default training function used in the MATLAB ANN.  Usually 
defaults to trainlm functions. 
trainb Trains a network using batch training by updating weight and bias 
learning rules 
trainc Trains a network cyclical order weight and bias learning rules 
traincgb Trains a network using conjugate gradient backpropagation in 
conjunction with Powell-Beale restarts to update weight and bias 
values 
traincgf Trains a network using conjugate gradient backpropagation in 
conjunction with Fletcher-Reeves updates to update weight and 
bias values 
traincgp Trains a network using conjugate gradient backpropagation in 
conjunction with Polak-Ribiere updates to update weight and bias 
values 
traingd Trains a network using gradient descent backpropagation to 
update weight and bias values 
traingda Trains a network using gradient descent with adaptive learning 
rate backpropagation to update weight and bias values 
traingdm Trains a network using gradient descent with momentum 
backpropagation to update weight and bias values 
traingdx Trains a network using gradient descent with momentum and 
adaptive learning rate backpropagation to update weight and bias 
values 
trainlm Trains a network using Levenberg-Marquardt backpropagation to 
update weight and bias values 
trainoss Trains a network using One-step secant backpropagation to 
update weight and bias values 
trainr Trains a network using random order incremental training with 
learning functions to update weight and bias values 
trainrp Trains a network using resilient backpropagation to update 
weight and bias values 
trains Trains a network using sequential order incremental training with 
learning functions to update weight and bias values 
trainscg Trains a network using scaled conjugate gradient 
backpropagation to update weight and bias values 
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Appendix F: Training Function Plots 
The following Figures F.1-F.15 show the actual disease values versus the ANN 
derived disease values for the 15 training functions tested in the ANN.  Each plot shows 
the three simulations run per training function, as well as a solid black line representing 
the desired one to one slope.  The one to one slope line makes it easier to distinguish 
whether individual trials and training functions as a whole were able to generate disease 
values similar to the actual values. 
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Figure F.1: Trainb Function Disease Plot 
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Figure F.2: Trainc Function Disease Plot 
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Figure F.3: Traincgb Function Disease Plot 
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Figure F.4: Traincgf Function Disease Plot 
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Figure F.5: Traincgp Function Disease Plot 
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Figure F.6: Traingd Function Disease Plot 
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Figure F.7: Traingda Function Disease Plot 
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Figure F.8: Traingdm Function Disease Plot 
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Figure F.9: Traingdx Function Disease Plot 
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Figure F.10: Trainlm Function Disease Plot 
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Figure F.11: Trainoss Function Disease Plot 
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Figure F.12: Trainr Function Disease Plot 
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Figure F.13: Trainrp Function Disease Plot 
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Figure F.14: Trains Function Disease Plot 
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Figure F.15: Trainscg Function Disease Plot 
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Appendix G: Uncurated chemical data 
Table G.1 contains the input data for each of the three uncurated chemicals used 
to test the predictability of the ANN.  The ANN derived species and disease outputs are 
also shown with the disease outputs round to the nearest whole number.  The rounding 
allowed the predictions to be matched up against the values used for the disease groups.  
The bolded rounded disease numbers and disease category outputs are those that have 
literature supporting the networks predictions.   
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